<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Sci</journal-id><journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2399</journal-id><journal-id journal-id-type="pmc-domain">brainsci</journal-id><journal-id journal-id-type="publisher-id">brainsci</journal-id><journal-title-group><journal-title>Brain Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3425</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10813099</article-id><article-id pub-id-type="pmcid-ver">PMC10813099.1</article-id><article-id pub-id-type="pmcaid">10813099</article-id><article-id pub-id-type="pmcaiid">10813099</article-id><article-id pub-id-type="pmid">38275511</article-id><article-id pub-id-type="doi">10.3390/brainsci14010006</article-id><article-id pub-id-type="publisher-id">brainsci-14-00006</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8503-8240</contrib-id><name name-style="western"><surname>Ying</surname><given-names initials="J">Jiangbo</given-names></name><xref rid="af1-brainsci-14-00006" ref-type="aff">1</xref><xref rid="fn1-brainsci-14-00006" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0969-7994</contrib-id><name name-style="western"><surname>Chew</surname><given-names initials="QH">Qian Hui</given-names></name><xref rid="af2-brainsci-14-00006" ref-type="aff">2</xref><xref rid="fn1-brainsci-14-00006" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuxi</given-names></name><xref rid="af1-brainsci-14-00006" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3209-9626</contrib-id><name name-style="western"><surname>Sim</surname><given-names initials="K">Kang</given-names></name><xref rid="af3-brainsci-14-00006" ref-type="aff">3</xref><xref rid="c1-brainsci-14-00006" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Siwek</surname><given-names initials="M">Marcin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-brainsci-14-00006"><label>1</label>East Region, Institute of Mental Health, Singapore 539747, Singapore</aff><aff id="af2-brainsci-14-00006"><label>2</label>Research Division, Institute of Mental Health, Singapore 539747, Singapore</aff><aff id="af3-brainsci-14-00006"><label>3</label>West Region, Institute of Mental Health, Singapore 539747, Singapore</aff><author-notes><corresp id="c1-brainsci-14-00006"><label>*</label>Correspondence: <email>kang_sim@imh.com.sg</email></corresp><fn id="fn1-brainsci-14-00006"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2024</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">454242</issue-id><elocation-id>6</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>19</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-22 03:25:24.250"><day>22</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="brainsci-14-00006.pdf"/><abstract><p>It is important to examine the psychotropic prescription practices in schizophrenia, as it can inform regarding changing treatment choices and related patient profiles. No recent reviews have evaluated the global neuropsychopharmacological prescription patterns in adults with schizophrenia. A systematic search of the literature published from 2002 to 2023 found 88 empirical papers pertinent to the utilization of psychotropic agents. Globally, there were wide inter-country and inter-regional variations in the prescription of psychotropic agents. Overall, over time there was an absolute increase in the prescription rate of second-generation antipsychotics (up to 50%), mood stabilizers (up to 15%), and antidepressants (up to 17%), with an observed absolute decrease in the rate of antipsychotic polypharmacy (up to 15%), use of high dose antipsychotic (up to 12% in Asia), clozapine (up to 9%) and antipsychotic long-acting injectables (up to 10%). Prescription patterns were mainly associated with specific socio-demographic (such as age), illness (such as illness duration), and treatment factors (such as adherence). Further work, including more evidence in adjunctive neuropsychopharmacological treatments, pharmaco-economic considerations, and examination of cohorts in prospective studies, can proffer insights into changing prescription trends relevant to different treatment settings and predictors of such trends for enhancement of clinical management in schizophrenia.</p></abstract><kwd-group><kwd>schizophrenia</kwd><kwd>antipsychotics</kwd><kwd>antidepressants</kwd><kwd>mood stabilizers</kwd><kwd>pharmacoepidemiology</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-brainsci-14-00006"><title>1. Introduction</title><p>Schizophrenia is a major mental illness characterized by positive symptoms, such as hallucinations and delusions, and negative symptoms, such as social withdrawal and amotivation [<xref rid="B1-brainsci-14-00006" ref-type="bibr">1</xref>]. The prevalent cases of schizophrenia globally have been on the rise, as evidenced by an increase in reported cases from 13.1 million in 1990 to 20.9 million in 2016, and this has contributed to a global disease burden of 13.4 million years of life lived with disability [<xref rid="B2-brainsci-14-00006" ref-type="bibr">2</xref>]. In the United States (US), the economic burden of schizophrenia has been reported to be more than 60 billion dollars per year [<xref rid="B3-brainsci-14-00006" ref-type="bibr">3</xref>] and in the United Kingdom (UK), the cost of schizophrenia has been estimated to be 6.7 billion pounds annually, with direct costs of 2 billion pounds on health and social care budgets [<xref rid="B4-brainsci-14-00006" ref-type="bibr">4</xref>]. Clearly, schizophrenia exerts a large burden on patients and society and needs appropriate treatment. </p><p>The treatment of schizophrenia involves pharmacological therapy in conjunction with psychosocial interventions, such as cognitive behavioral therapy, social support, and rehabilitation [<xref rid="B5-brainsci-14-00006" ref-type="bibr">5</xref>]. Antipsychotics (APs) are the primary psychotropic medications to treat schizophrenia. Many different APs, such as haloperidol, olanzapine, risperidone, and clozapine (CLZ), have been assessed for their efficacy and safety in controlling psychotic symptoms [<xref rid="B6-brainsci-14-00006" ref-type="bibr">6</xref>,<xref rid="B7-brainsci-14-00006" ref-type="bibr">7</xref>,<xref rid="B8-brainsci-14-00006" ref-type="bibr">8</xref>]. APs are particularly effective in treating positive symptoms, but they have limited effectiveness in treating negative symptoms [<xref rid="B9-brainsci-14-00006" ref-type="bibr">9</xref>]. Over the past few years, research has suggested the pathophysiology of schizophrenia may go beyond the dopamine hypothesis and involve other molecular targets, such as glutamatergic, cholinergic, and gamma-aminobutyric acid (GABA) receptors [<xref rid="B10-brainsci-14-00006" ref-type="bibr">10</xref>,<xref rid="B11-brainsci-14-00006" ref-type="bibr">11</xref>]. Other psychotropic medications, such as mood stabilizers (MSs) and antidepressants (ADs), have been examined as adjuvants to APs in the treatment of symptoms such as aggression [<xref rid="B12-brainsci-14-00006" ref-type="bibr">12</xref>] and negative symptoms [<xref rid="B13-brainsci-14-00006" ref-type="bibr">13</xref>]. Lithium, which has been the mainstay treatment for bipolar disorder [<xref rid="B14-brainsci-14-00006" ref-type="bibr">14</xref>], acts on the GABA receptor to restore the excitatory&#8211;inhibitory neurotransmitter levels [<xref rid="B15-brainsci-14-00006" ref-type="bibr">15</xref>]. Valproate also acts on the GABA receptor and may target other signaling pathways, such as arachidonic acid cascade [<xref rid="B16-brainsci-14-00006" ref-type="bibr">16</xref>]. ADs modulate several neurotransmitter systems, including the monoaminergic system [<xref rid="B17-brainsci-14-00006" ref-type="bibr">17</xref>]. It has been reported that add-on citalopram may reduce the level of negative symptoms in schizophrenia [<xref rid="B18-brainsci-14-00006" ref-type="bibr">18</xref>]. </p><p>Although there are treatment guidelines for schizophrenia, prescription patterns of psychotropic medications are often influenced by many other factors, such as the clinician&#8217;s own training, local prescription practices, the nature of the healthcare system, and the delivery of healthcare [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]. It has been reported that treatment guidelines may not fully reflect routine clinical practice [<xref rid="B20-brainsci-14-00006" ref-type="bibr">20</xref>]. For example, psychiatrists in Japan frequently prescribed antipsychotic polypharmacy (APP) due to their positive attitudes towards this practice [<xref rid="B21-brainsci-14-00006" ref-type="bibr">21</xref>]; and in Asia, depot APs were prescribed to improve treatment adherence in severely ill hospitalized individuals [<xref rid="B22-brainsci-14-00006" ref-type="bibr">22</xref>]. There have been cross-sectional or cohort studies that explored the prescription patterns for schizophrenia. One study in Asia found that among 3537 patients with schizophrenia, 31.3% and 80.8% received first- and second-generation APs, respectively, and 13.7% were prescribed an MS [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]. Another study assessed 2003 patients in Asia and found that 82.14% received APs and 14.7% had MS monotherapy [<xref rid="B23-brainsci-14-00006" ref-type="bibr">23</xref>]. To the best of our knowledge, there are no recent studies that have examined the global psychotropic prescription trends in schizophrenia. </p><p>It is important to understand the psychotropic prescription patterns in schizophrenia, as it can inform regarding changing treatment choices and related patient profiles. Understanding clinical correlates and outcomes associated with different prescription trends can potentially help clinicians identify clinical profiles that may benefit from certain psychotropic medications. In addition, knowing the details of prescription practices allows healthcare professionals to balance the potential benefits of medications with their side effects and risks. Thus, the aims of the current study were to: (1) assess the global patterns of real-world psychotropic agents (APs, MSs, ADs) used in adult patients with schizophrenia spectrum disorder; and (2) evaluate the inter-relationships between psychotropic medication use and clinical correlates. This study would address the gap in existing research by providing a comprehensive and up-to-date summary of the worldwide psychotropic prescription patterns in schizophrenia. </p></sec><sec id="sec2-brainsci-14-00006"><title>2. Materials and Methods</title><p>This study utilized the five-step framework developed by Arksey and O&#8217;Malley for scoping reviews [<xref rid="B24-brainsci-14-00006" ref-type="bibr">24</xref>] to direct the process. The first step consisted of identifying the main research questions explored in our review, which were: (1) What were the prescription patterns of psychotropic medications in adult patients with schizophrenia spectrum disorder? and (2) What were the inter-relationships between psychotropic agent use and clinical correlates?</p><p>The second step focused on the identification of relevant studies. The literature search was performed on the PubMed database for articles published between January 2002 and November 2023 by including the keyword &#8220;schizophrenia&#8221; in the title/abstract of the article together with a combination of the following keywords related to psychotropic medication (&#8220;psychotropic*&#8221;, &#8220;antipsychotic*&#8221;, &#8220;antidepressant*&#8221;, &#8220;mood stabilizer*&#8221;, &#8220;medication&#8221;, &#8220;drug*&#8221;). The keywords &#8220;pattern&#8221;, &#8220;epidemiolog*&#8221;, &#8220;pharmacoepidemiolog*&#8221;, &#8220;trend*&#8221;, &#8220;prevalence&#8221;, &#8220;frequency&#8221;, and &#8220;percentage&#8221; were used to specify the topic of interest, and the search was restricted to certain study designs using the keywords &#8220;cross-sectional&#8221;, &#8220;register&#8221;, &#8220;claim&#8221;, &#8220;cohort&#8221;, and &#8220;observational&#8221;. </p><p>The third step involved the study selection. According to the inclusion criteria and exclusion criteria, all authors J.Y., Q.H.C., Y.X.W. and K.S. independently screened the retrieved literature. In the case of a disagreement, all authors (J.Y., Q.H.C., Y.X.W. and K.S.) would discuss until a consensus was reached. Selection criteria were as follows: <list list-type="simple"><list-item><label>(1)</label><p>Original papers published in English.</p></list-item><list-item><label>(2)</label><p>Findings that were specific to adult patients with schizophrenia spectrum disorder.</p></list-item><list-item><label>(3)</label><p>Available data on psychotropic prescription patterns.</p></list-item></list></p><p>Exclusion criteria included: <list list-type="simple"><list-item><label>(1)</label><p>Results are specific to a particular sub-population only (e.g., elderly, child/adolescent, pregnant women).</p></list-item><list-item><label>(2)</label><p>Results are specific to a certain psychotropic medication class (e.g., depot AP only, olanzapine vs. risperidone only).</p></list-item><list-item><label>(3)</label><p>Review papers, such as meta-analyses and systematic reviews.</p></list-item></list></p><p>The fourth and fifth steps encompassed the data collection, summarization, and reporting of findings. For each included study, we extracted variables including the characteristics of subjects, nature and aim of the study, type, and prevalence of APs, MSs, and ADs prescribed, as well as the main correlates reported. </p></sec><sec sec-type="results" id="sec3-brainsci-14-00006"><title>3. Results</title><p>There was a total of 88 studies included in our review published from 2002 to 2023. The PRISMA flowchart of the papers screened and included is shown in <xref rid="brainsci-14-00006-f001" ref-type="fig">Figure 1</xref>. The main details of the included studies are shown in <xref rid="app1-brainsci-14-00006" ref-type="app">Table S1 in the Supplementary Materials</xref>. There was an average of 20,819 participants in 87 studies that reported sample sizes. The percentage of male participants ranged from 31.9 to 95 in 71 studies that reported this data. Participants were 41.6 years old on average based on 41 studies. The majority of the studies were conducted in Asia (27 studies, 30.7%), followed by the US and Canada (26 studies, 29.5%), and the UK and Europe (24 studies, 27.3%). A small number of studies were also conducted in Africa (five studies, 5.7%), Australia and New Zealand (three studies, 3.4%), Brazil (one study, 1.1%) and across regions (two studies, 2.3%).</p><sec id="sec3dot1-brainsci-14-00006"><title>3.1. Antipsychotic Prescription Trends and Clinical Correlates</title><p>APs are generally regarded as the first-line treatment for patients with schizophrenia and were given to the majority of these patients, although a sizable number of studies reported patients who received no dispensed APs. The frequency of AP use was 67&#8211;98.8% in schizophrenia patients in these studies [<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>,<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B30-brainsci-14-00006" ref-type="bibr">30</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B33-brainsci-14-00006" ref-type="bibr">33</xref>,<xref rid="B34-brainsci-14-00006" ref-type="bibr">34</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>,<xref rid="B37-brainsci-14-00006" ref-type="bibr">37</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>]. Most patients (52.3% to 90.9%) were on AP monotherapy [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B30-brainsci-14-00006" ref-type="bibr">30</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B34-brainsci-14-00006" ref-type="bibr">34</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B42-brainsci-14-00006" ref-type="bibr">42</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>], except for five studies [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B53-brainsci-14-00006" ref-type="bibr">53</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B56-brainsci-14-00006" ref-type="bibr">56</xref>]. Monotherapy AP prescription generally showed an upward trend over the years [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>], particularly for second-generation AP (SGA) monotherapy [<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>]. Monotherapy is generally more frequent in patients receiving SGA [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B56-brainsci-14-00006" ref-type="bibr">56</xref>,<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>], particularly those initiated on olanzapine [<xref rid="B53-brainsci-14-00006" ref-type="bibr">53</xref>]. Nonetheless, there were several earlier studies reporting higher rates of first-generation AP (FGA) as compared to SGA monotherapy [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>].</p><p>Most studies reported greater SGA use (ranging from 31.2% to 93.1%) [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B62-brainsci-14-00006" ref-type="bibr">62</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B66-brainsci-14-00006" ref-type="bibr">66</xref>,<xref rid="B67-brainsci-14-00006" ref-type="bibr">67</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>] as compared to FGA (8.9% to 71.3%) [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B62-brainsci-14-00006" ref-type="bibr">62</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B66-brainsci-14-00006" ref-type="bibr">66</xref>,<xref rid="B67-brainsci-14-00006" ref-type="bibr">67</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>]. Prescription rates of FGA fell over the years (by 11&#8211;26.1%) [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B72-brainsci-14-00006" ref-type="bibr">72</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>], except for one study [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>]. Use of SGA increased over time (by 3.2&#8211;73.9%) [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B72-brainsci-14-00006" ref-type="bibr">72</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>], and more than doubled over seven years in one study (rates of use from 27.5% to 76.9%) [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>]. </p><p>Risperidone (16.3&#8211;44.8%) was the most prescribed oral AP in seven studies [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B67-brainsci-14-00006" ref-type="bibr">67</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B76-brainsci-14-00006" ref-type="bibr">76</xref>], or among the top few in other studies (12.5&#8211;69.2%) [<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>]. Olanzapine (13.7&#8211;91.3%) [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B81-brainsci-14-00006" ref-type="bibr">81</xref>,<xref rid="B82-brainsci-14-00006" ref-type="bibr">82</xref>], quetiapine (7.6&#8211;17.8%) [<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], aripiprazole (11.6&#8211;31.9%) [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>] and haloperidol (17.9&#8211;62%) [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>] were also frequently prescribed. Studies investigating trends in AP use reported that ziprasidone [<xref rid="B83-brainsci-14-00006" ref-type="bibr">83</xref>], olanzapine [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>], and quetiapine [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>] use increased significantly over time, while haloperidol use fell [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>]. Mixed results were reported for aripiprazole [<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>] and risperidone [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>]. </p><p>Factors associated with the prescription of an SGA included younger age [<xref rid="B84-brainsci-14-00006" ref-type="bibr">84</xref>], and shorter duration of hospitalization [<xref rid="B84-brainsci-14-00006" ref-type="bibr">84</xref>]. Those on SGA also had a lower score on aggression regardless of dose [<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>]. Factors associated with the prescription of an FGA included anticholinergic use [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>] and having received inpatient treatment in the past year [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>]. </p><sec id="sec3dot1dot1-brainsci-14-00006"><title>3.1.1. Dosing of Antipsychotic Prescribed</title><p>Approximately 80% of schizophrenia patients were on a dose of less than 600 mg chlorpromazine (CPZ) equivalents/day [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>]. The average AP dose in studies based in Asia ranged from 273 mg to 683.5 mg CPZ equivalents/day [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>], compared with 232 mg CPZ equivalents/day [<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>] in Denmark, and 467 mg CPZ equivalents/day in the US [<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>].</p><p>Higher mean daily doses were associated with use of high-potency agents [<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>], more recurrent episodes of illness [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>], inpatient treatment in the past year [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>], use of adjunctive MS [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>], being male [<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>,<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>], younger age [<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>], being Indigenous Australians [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>], and being under involuntary treatment [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>]. One study found that the mean dose of APs increased over the years, with the CPZ equivalent dose/day doubling from 1996 to 2005 [<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>], although others reported a decrease [<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>]. </p><p>High-dose AP prescription rates varied according to definitions. When determined as the ratio of prescribed daily dose (PDD) to defined daily dose (DDD) greater than 1.5 (PDD/DDD &gt; 1.5), the high dose prescription rate ranged between 18.4&#8211;45.3% [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>], and was 8.1% when defined by British National Formulary (BNF) percentage exceeding 100%, (BNF &gt; 100%) [<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>], and 2.2%&#8211;17.9% when using CPZ equivalents &gt; 1000 mg in patients with schizophrenia [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>,<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>]. When defined as &gt;1200 mg CPZ equivalents, the high-dose AP prescription rate was 4.7% [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]. One study involving a population of patients with severe and persistent schizophrenia reported an average CPZ equivalent dose of 1386.6 mg/day [<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>]. Of note, studies found that AP drugs were under-dosed at a rate of 26.7% [<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>], and excessively dosed in 0.8% of patients when compared to treatment guidelines [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>]. Patients on polypharmacy with AP long-acting injectable (LAI) were more likely to be on doses above the BNF limit compared to those on oral-only APP [<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>]. </p><p>Over time, the high-dose AP prescription rate decreased [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>], with the absolute rate more than halved within Asia from 17.9% in 2001 to 6.5% in 2004 [<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>]. In a separate study in Korea, there was a downward trend of high-dose AP monotherapy prescription (30.4% to 18.4%) [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>] but an upward trend for high-dose APP (34% to 45.3%) [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>]. </p><p>High-dose AP prescription was associated with sociodemographic factors (such as male gender), treatment factors (such as APP and inpatient treatment), and illness factors (such as first-episode psychosis and severe psychopathology). Details of the various clinical correlates with high-dose AP use are seen in <xref rid="brainsci-14-00006-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3dot1dot2-brainsci-14-00006"><title>3.1.2. Antipsychotic Treatment Adherence and Discontinuation</title><p>For first-line treatment, oral APs were the preferred choice, with 71% of patients with schizophrenia who initiated treatment for the first time being given an oral AP [<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>]. CLZ (34%) and FGA LAI (34%) were the preferred choice for second-line or later treatments [<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>]. Nonetheless, adherence to AP treatment could wane, with less than half of the patients continuing their treatment beyond one year in Italy, Spain, the UK and the US [<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>], and was especially associated with APP [<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>], alcohol abuse/dependence [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], use of MSs [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], involuntary admission [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], prior arrests [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], greater symptom severity [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], previous AP use [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], lack of social activities [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], as well as age below 25 years [<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>]. In comparison to those with a more continuous pattern of AP treatment, patients who engaged in moderate or light usage had 52% or 72% increased odds of hospitalization for schizophrenia [<xref rid="B95-brainsci-14-00006" ref-type="bibr">95</xref>]. In addition, poor treatment adherence resulted in an average length of hospitalization that was 20% longer than that of those who were adherent to treatment [<xref rid="B95-brainsci-14-00006" ref-type="bibr">95</xref>]. </p><p>Male gender [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>], older age [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>], and use of AD [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>] were associated with lower likelihood of treatment discontinuation. The likelihood of drug switching was higher for those who were inpatients [<xref rid="B57-brainsci-14-00006" ref-type="bibr">57</xref>] and with SGA use [<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>]. CLZ [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>] and olanzapine use [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>] had the highest frequency of medication maintenance at 12 months while quetiapine and amisulpride had the lowest in a previous study [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>]. Switching and augmentation of initial AP medication was associated with significant increases in healthcare costs compared to monotherapy [<xref rid="B30-brainsci-14-00006" ref-type="bibr">30</xref>]. The main reason cited for an AP switch/discontinuation was ineffectiveness [<xref rid="B37-brainsci-14-00006" ref-type="bibr">37</xref>,<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>].</p></sec><sec id="sec3dot1dot3-brainsci-14-00006"><title>3.1.3. Antipsychotic Long-Acting Injectables</title><p>Most studies reported limited use of AP LAI (2% to 25%) [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B62-brainsci-14-00006" ref-type="bibr">62</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B72-brainsci-14-00006" ref-type="bibr">72</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>], while a few studies reported significant use of AP LAI (35.6% to 58%) [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>]. The most common AP LAI used were risperidone (38.8%) [<xref rid="B97-brainsci-14-00006" ref-type="bibr">97</xref>], zuclopenthixol (11.4&#8211;17.8%) [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B97-brainsci-14-00006" ref-type="bibr">97</xref>], and fluphenazine (5.4&#8211;52.4%) [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B97-brainsci-14-00006" ref-type="bibr">97</xref>]. Out of all schizophrenia patients on LAI, a significant proportion were on an FGA LAI (48.9&#8211;56.6%) [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B97-brainsci-14-00006" ref-type="bibr">97</xref>], and associated with concomitant oral AP use at the one-year follow-up period [<xref rid="B97-brainsci-14-00006" ref-type="bibr">97</xref>]. </p><p>There was an overall decrease in LAI prescription over time in Asia (2.6% to 9.5% drop) [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>] and some Western countries [<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>]. However, this differed by type of AP LAI. There was a 4&#8211;7% increase in the proportion of SGA LAI prescriptions [<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>] and a 13&#8211;19% increase in the proportion of FGA LAI prescriptions from 2013 to 2017 [<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>] in one study in Australia, while another study reported a 7.8% drop in FGA LAI prescriptions from 2000 to 2003 [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>].</p><p>Only one study explored correlates with AP LAI use in a regression model and found that those treated with FGA LAI tended to be African American and non-veterans, had a history of prior arrests and alcohol and illicit substance use, and had greater symptom severity and psychiatric hospitalization in the previous year [<xref rid="B98-brainsci-14-00006" ref-type="bibr">98</xref>]. Although SGA LAI use (21%) was lower than that of FGA LAI (34%) and CLZ (34%) in second-line or later treatments for schizophrenia patients, Pai and colleagues [<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>] reported that adherence to SGA LAI was better than other treatment modalities. </p></sec><sec id="sec3dot1dot4-brainsci-14-00006"><title>3.1.4. Antipsychotic Polypharmacy</title><p>Observational studies reported APP rates of approximately 3.7&#8211;57.7% in the US [<xref rid="B30-brainsci-14-00006" ref-type="bibr">30</xref>,<xref rid="B34-brainsci-14-00006" ref-type="bibr">34</xref>,<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B53-brainsci-14-00006" ref-type="bibr">53</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B101-brainsci-14-00006" ref-type="bibr">101</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>,<xref rid="B103-brainsci-14-00006" ref-type="bibr">103</xref>], 2.3&#8211;69.9% in Europe [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], 50.9% to 70.4% in Nigeria [<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>], 22.7&#8211;28.2% in Ethiopia [<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>], 67% in Uzbekistan [<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>], 43.9% in India [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>], 19.9&#8211;44% in Japan [<xref rid="B37-brainsci-14-00006" ref-type="bibr">37</xref>,<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>], 8.3% to 34.2% in China and Taiwan [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>], 48.3% in Korea [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>], 20% in Australia [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>], and 40.1&#8211;45.7% across several Asian countries [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>,<xref rid="B105-brainsci-14-00006" ref-type="bibr">105</xref>]. </p><p>The combination of two FGA was common in Ethiopia and Nigeria (13.5&#8211;44.4%) [<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>], although this combination decreased over the years [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], being replaced by the increased preference of two SGA in combination therapy (up to 41.7% out of all patients) [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], or a combination of FGA and SGA [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>]. Rates of SGA combination therapy ranged from 6.4&#8211;57.7% out of the entire cohort of patients [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>], while a combination of FGA and SGA was prescribed at a rate of 2.1&#8211;55.3% [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>,<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B67-brainsci-14-00006" ref-type="bibr">67</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>,<xref rid="B84-brainsci-14-00006" ref-type="bibr">84</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>].</p><p>On average, each clinician had an average of 7% &#177; 9% of patients with APP [<xref rid="B106-brainsci-14-00006" ref-type="bibr">106</xref>], and it was observed in the same study that prescribers who managed patients with a high frequency of schizophrenia-related hospitalizations, or those with a larger proportion of Hispanic or non-Hispanic black patients, a smaller percentage of patients with disabilities, and those with a low overall volume of AP prescriptions were much less likely to be associated with APP versus prescribers with less severely ill patients [<xref rid="B106-brainsci-14-00006" ref-type="bibr">106</xref>]. The main reason cited by clinicians for an increase in the number of AP prescribed was &#8220;ineffectiveness&#8221; during clinical management [<xref rid="B37-brainsci-14-00006" ref-type="bibr">37</xref>].</p><p>APP was associated with socio-demographic factors (such as males and living alone), treatment factors (such as long-acting AP injectable use, CLZ use, inpatient setting, greater number of hospitalizations, and non-treatment adherence), and illness factors (such as longer illness duration and more psychiatric comorbidities). Details of the various clinical correlates with APP are seen in <xref rid="brainsci-14-00006-t002" ref-type="table">Table 2</xref>. </p><p>In terms of changes over time, five studies on prescription trends showed that APP generally increased over the years [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], and approximately doubled in two studies [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>]. This was particularly true for SGA APP (up to 40% increase) [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>]. However, there was the suggestion of a slight decline in APP in recent years, particularly among those with chronic schizophrenia [<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>]. Seven studies reported a reduction of between 1.2% to 14.9% [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>].</p><p>In terms of the number of APs, of note, 9.1&#8211;57.7% of patients were on two AP medications [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], up to 38.4% of patients were on three APs [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], and 0.12&#8211;10.1% were on four or more APs [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>], with 1.6% on doses that exceeded the maximum dose [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>]. </p><p>In terms of doses of APP, the CPZ equivalent dosage of AP for patients on APP ranged from 380.3 to 1386.6 mg/day [<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>]. Patients on APP received lower dosages of first-generation agents compared to those on monotherapy [<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]. However, patients on APP tended to receive more than twice the AP dose compared to those on AP monotherapy [<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>]. </p></sec><sec id="sec3dot1dot5-brainsci-14-00006"><title>3.1.5. Clozapine Use</title><p>There was a wide range of prescription rates for CLZ in both Europe and the US, ranging from 3&#8211;22.7% in Europe [<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>] and from 2&#8211;46.2% in the US [<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>,<xref rid="B42-brainsci-14-00006" ref-type="bibr">42</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B108-brainsci-14-00006" ref-type="bibr">108</xref>]. In non-European countries, rates of CLZ use were 3.8% in Nepal [<xref rid="B61-brainsci-14-00006" ref-type="bibr">61</xref>], 66% in Uzbekistan [<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>], and 35% in New Zealand [<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>], 25% in Australia [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>]. Studies across several Asian countries reported rates of 15.6&#8211;18.9% [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>], although studies in specific Asian countries suggested significant inter-country differences. Rates of CLZ use in China were generally high (15.6&#8211;44%) [<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B84-brainsci-14-00006" ref-type="bibr">84</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>], and CLZ was the most widely prescribed AP in three studies [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>]. The use of CLZ in schizophrenia patients in Japan was comparatively limited, with rates of 0.2&#8211;7.1% being reported [<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>]. CLZ prescription fell significantly over time [<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>], by approximately 50% in one study from 18% in 1998 to 9% in 2003 [<xref rid="B72-brainsci-14-00006" ref-type="bibr">72</xref>], although four studies reported an increase in CLZ use [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B49-brainsci-14-00006" ref-type="bibr">49</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>]. CLZ use increased from admission to discharge for patients with schizophrenia [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>].</p><p>In an earlier study, it was noted that each clinician had an average of 7% &#177; 10% of patients with CLZ use [<xref rid="B106-brainsci-14-00006" ref-type="bibr">106</xref>]. Prescribers were less likely to use CLZ if they had a larger proportion of Hispanic and non-Hispanic black patients, a smaller proportion of patients with disabilities, or a low volume of AP prescriptions overall [<xref rid="B106-brainsci-14-00006" ref-type="bibr">106</xref>].</p><p>Patients on CLZ had the highest frequency of medication maintenance over time (79.5&#8211;83.9%) [<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], and had a lower discontinuation rate compared with olanzapine and risperidone [<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>]. In terms of CLZ dosing, patients on CLZ received a mean dose ranging from 69 to 507.7 mg/day [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>].</p></sec></sec><sec id="sec3dot2-brainsci-14-00006"><title>3.2. Mood Stabilizer Prescription Trends</title><p>Adjunctive MS was prescribed at a rate of 13.6&#8211;51.6% in the US [<xref rid="B33-brainsci-14-00006" ref-type="bibr">33</xref>,<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B103-brainsci-14-00006" ref-type="bibr">103</xref>,<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>], 3.1&#8211;28.5% in Europe [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B56-brainsci-14-00006" ref-type="bibr">56</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>,<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>], and 0.9% in Nigeria [<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>]. Adjunctive MS use was highest in Italy when compared to European countries [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>]. In Asia, the rates were 4.2&#8211;19.4% in China and Taiwan [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>], 20.9% in Korea [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>], and 22.1&#8211;37% in Japan [<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>]. A study across several Asian countries reported rates of 13.6&#8211;23.7% [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>], with 12.8% on one MS, 0.76% on two MS, and 0.03% on three MS [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>]. </p><p>Rates specific to adjunctive lithium use were low and largely similar across countries, ranging from 2.6&#8211;7.8% in Europe [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>], 1.7&#8211;6.6% in the US [<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>], and 1.6&#8211;5.1% in Asia [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>]. Overall, the most commonly prescribed MS was valproate (4.4&#8211;16.7%) [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>,<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>]. </p><p>Prescription rates of adjunctive MS for schizophrenia patients generally increased over the years [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>] by between 3.5% to 15.2% [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>]. The use of valproate increased significantly over the years [<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>], while the use of lithium and carbamazepine declined [<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B72-brainsci-14-00006" ref-type="bibr">72</xref>,<xref rid="B81-brainsci-14-00006" ref-type="bibr">81</xref>]. In terms of dosing, the average MS dose was 613 &#177; 456 mg/day Li equivalents in a study within an Asian research consortium involving schizophrenia patients [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>].</p><p>Adjunctive MS use was associated with illness factors (such as longer duration of illness, aggression, affective symptoms, and previous suicidality) and treatment factors (such as APP and AD use). Details of the various clinical correlates with adjunctive MS use are seen in <xref rid="brainsci-14-00006-t003" ref-type="table">Table 3</xref>. </p></sec><sec id="sec3dot3-brainsci-14-00006"><title>3.3. Antidepressant Prescription Trends</title><p>The prevalence of adjunctive AD use was 4.4&#8211;27.4% in China and Hong Kong [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B46-brainsci-14-00006" ref-type="bibr">46</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>], 47.7% in Taiwan [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>], 8&#8211;42.3% in Japan [<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>], 8.5% in Korea [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>], and 8.7&#8211;11.7% in several countries across Asia [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>]. Adjunctive AD was prescribed at rates of 30.8&#8211;56.2% in the US [<xref rid="B33-brainsci-14-00006" ref-type="bibr">33</xref>,<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B59-brainsci-14-00006" ref-type="bibr">59</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B103-brainsci-14-00006" ref-type="bibr">103</xref>], 5.4&#8211;45.7% in Europe [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B62-brainsci-14-00006" ref-type="bibr">62</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B81-brainsci-14-00006" ref-type="bibr">81</xref>,<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>,<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>], 4.4% in Nigeria [<xref rid="B77-brainsci-14-00006" ref-type="bibr">77</xref>], and 36% in Uzbekistan [<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>]. AD use was highest in the UK/Ireland and France across Western countries [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>]. </p><p>Prescription of adjunctive AD for schizophrenia generally exhibited an upward trend over the years [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B81-brainsci-14-00006" ref-type="bibr">81</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], and nearly doubled in two studies (18.5% in 1995 to 35.6% in 1999 [<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>], 24.3% in 1996 to 40.6% in 2005 [<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>]). In terms of dosing, the mean annual DDD for AD prescriptions increased over time [<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>]. </p><p>The following factors were associated with more AD use: female gender [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], younger age [<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], less severe illness/fewer positive symptoms [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], more depressive symptoms [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], less use of FGA [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>], more use of benzodiazepines (BZD) [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B70-brainsci-14-00006" ref-type="bibr">70</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], current or prior use of an MS [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], use of anticholinergic/anti-Parkinsonian drugs [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], earlier age of onset of illness [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>], co-occurring depression, post-traumatic stress disorder (PTSD) or substance use disorder [<xref rid="B111-brainsci-14-00006" ref-type="bibr">111</xref>], previous suicidality [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], outpatient in a tertiary/specialty treatment center [<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>,<xref rid="B111-brainsci-14-00006" ref-type="bibr">111</xref>], no previous psychosis episodes requiring inpatient care [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>], better compliance [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], experiencing loss of libido as a side effect [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], and no history of homelessness [<xref rid="B111-brainsci-14-00006" ref-type="bibr">111</xref>]. </p></sec><sec id="sec3dot4-brainsci-14-00006"><title>3.4. Prescription Trends of Other Psychotropic Medications</title><sec id="sec3dot4dot1-brainsci-14-00006"><title>3.4.1. Anticholinergics</title><p>Anticholinergics were prescribed at a rate of 9&#8211;63.7% in patients with schizophrenia [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B66-brainsci-14-00006" ref-type="bibr">66</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>]. Anticholinergic use was highest in the UK/Ireland and Greece across Western countries [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>]. Anticholinergic dosages were higher in those with high AP doses [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>], those on APP [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>], and those on FGA [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>]. </p><p>Anticholinergics were used with decreasing frequency over the years in four studies [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], although another study reported approximately 5% increase over five years [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>], noted from admission to discharge (9.3% to 11.6%) [<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>]. An anticholinergic prescription was associated with patient non-compliance [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], absence of substance abuse [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], prior olanzapine or CLZ use [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], more positive symptoms [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], more extra-pyramidal side effects (EPSE) [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], high-dose AP use [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>], APP [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>], and use of FGA monotherapy [<xref rid="B86-brainsci-14-00006" ref-type="bibr">86</xref>]. Patients treated with a combination of LAI and oral APs [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>] or on any FGA [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>] were significantly more likely to be prescribed anticholinergics, versus SGA [<xref rid="B66-brainsci-14-00006" ref-type="bibr">66</xref>]. </p></sec><sec id="sec3dot4dot2-brainsci-14-00006"><title>3.4.2. Benzodiazepines</title><p>There were large variations in rates of prescription of adjunctive BZD with anxiolytic and hypnotic properties across countries. In a study surveying several countries within Asia, the average rate of BZD prescription was 27.8%. The lowest rate (8.6%) was in Hong Kong [<xref rid="B74-brainsci-14-00006" ref-type="bibr">74</xref>], while the highest (89.4%) was reported in Taiwan [<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>]. Rates of BZD use in other Asian countries were as follows: China (19.6&#8211;31.6%) [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B64-brainsci-14-00006" ref-type="bibr">64</xref>], Korea (58.7%) [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>], and Japan (49.9&#8211;68%) [<xref rid="B44-brainsci-14-00006" ref-type="bibr">44</xref>,<xref rid="B47-brainsci-14-00006" ref-type="bibr">47</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>]. </p><p>Similarly, in Europe, the average prescription rate was 26.8% [<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], with the lowest reported in Sweden (6&#8211;32.8%) [<xref rid="B25-brainsci-14-00006" ref-type="bibr">25</xref>,<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>], and the highest in Austria (89.7%) [<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>]. Rates in other European countries were as follows: 22.3% in Finland [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>], 28.1% in France [<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>], 40&#8211;54.8% in Spain [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B62-brainsci-14-00006" ref-type="bibr">62</xref>], 36.2&#8211;54.3% in Belgium [<xref rid="B29-brainsci-14-00006" ref-type="bibr">29</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>], 37% in Germany [<xref rid="B32-brainsci-14-00006" ref-type="bibr">32</xref>], 37.77% in Romania [<xref rid="B56-brainsci-14-00006" ref-type="bibr">56</xref>], and 47% in Italy [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>]. Rates of use in the US saw smaller variations, ranging from 14.6&#8211;33.5% in several studies [<xref rid="B26-brainsci-14-00006" ref-type="bibr">26</xref>,<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B71-brainsci-14-00006" ref-type="bibr">71</xref>,<xref rid="B78-brainsci-14-00006" ref-type="bibr">78</xref>,<xref rid="B103-brainsci-14-00006" ref-type="bibr">103</xref>,<xref rid="B108-brainsci-14-00006" ref-type="bibr">108</xref>]. There was a trend of increased adjunctive BZD use over the years in Europe [<xref rid="B35-brainsci-14-00006" ref-type="bibr">35</xref>,<xref rid="B80-brainsci-14-00006" ref-type="bibr">80</xref>], but a slight decrease was reported in another study based in Asia [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>].</p><p>BZD use was associated with older age [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], lower education levels [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>], and those living in areas of low or high population density [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>], greater symptom severity [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], more hostility/aggressiveness [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B85-brainsci-14-00006" ref-type="bibr">85</xref>], more anxiety symptoms [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>], APP or more AP use [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>], more anticholinergic use [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>], a higher number of hospitalizations in the past year [<xref rid="B31-brainsci-14-00006" ref-type="bibr">31</xref>], more EPSE [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], loss of libido [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>], and mortality especially in those with chronic high-dose use [<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>].</p></sec></sec></sec><sec sec-type="discussion" id="sec4-brainsci-14-00006"><title>4. Discussion</title><p>This review sought to review global real-world psychotropic prescription trends in schizophrenia and there were several main findings. Globally, there were wide inter-country and inter-regional variations in the prescription of APs, MSs, and ADs. Overall, over time there was an absolute increase in the prescription rate of SGA (increase up to 50%), MSs (increase up to 15%) and ADs (increase up to 17%), with an observed absolute decrease in the rate of APP (decrease up to 15%), use of high dose APs (decrease up to 12% in Asia), CLZ (decrease up to 9%) and LAIs (decrease up to 10%). Prescription patterns of the different agents were associated with specific socio-demographic (such as age, and gender), illness (such as illness duration, nature and severity of psychopathology, and psychiatric and medical comorbidities), and treatment factors (such as treatment setting, and adherence). </p><p>The frequency of AP use ranged from 67% to 98.8%, instead of 100%, though APs are regarded as the primary psychotropic agent to treat schizophrenia. There are several possible explanations. Some patients with schizophrenia may be mildly ill or in remission from their illness, hence APs may not be used [<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>]. In addition, it is possible for studies to have incomplete data, coding errors, and reporting errors [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B39-brainsci-14-00006" ref-type="bibr">39</xref>], leading to the possibility of patients not on any recorded APs. </p><p>Our review found that the frequency of SGA use increased and more than doubled over time in three studies [<xref rid="B43-brainsci-14-00006" ref-type="bibr">43</xref>,<xref rid="B55-brainsci-14-00006" ref-type="bibr">55</xref>,<xref rid="B73-brainsci-14-00006" ref-type="bibr">73</xref>], while the prescription rate of FGA decreased. SGA is effective in ameliorating positive psychotic psychopathology, has mood stabilizing effects [<xref rid="B112-brainsci-14-00006" ref-type="bibr">112</xref>] and fewer EPSE [<xref rid="B113-brainsci-14-00006" ref-type="bibr">113</xref>], and is recommended as a first-line agent over FGA in most treatment guidelines [<xref rid="B114-brainsci-14-00006" ref-type="bibr">114</xref>]. This likely explains the notable change in AP prescription patterns with the increased use of SGA over time. The use of SGA was found to be associated with younger age and shorter duration of hospitalization which could relate to the presentation of positive symptoms at earlier presentations, and its less propensity for EPSE. However, SGAs are associated with weight gain and other metabolic side effects [<xref rid="B115-brainsci-14-00006" ref-type="bibr">115</xref>,<xref rid="B116-brainsci-14-00006" ref-type="bibr">116</xref>], thus clinicians should carefully consider the side effect profile when recommending APs to patients including SGA. </p><p>We found a significant concern regarding treatment adherence with AP treatment, as less than half of the patients continued the treatment in several studies [<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>,<xref rid="B93-brainsci-14-00006" ref-type="bibr">93</xref>]. Poor AP adherence can potentially cause serious clinical consequences, such as relapse of psychotic illness, suicide attempts, and readmissions [<xref rid="B117-brainsci-14-00006" ref-type="bibr">117</xref>] and treatment discontinuation can actually paradoxically increase the total healthcare costs [<xref rid="B118-brainsci-14-00006" ref-type="bibr">118</xref>]. Although the choice of discontinuing AP agents after a period of time may be driven by concerns about safety and impact on their quality of life, it has been found that maintenance on AP drugs not only prevented relapses and readmissions but was also associated with improvements in quality of life and functioning within patients [<xref rid="B119-brainsci-14-00006" ref-type="bibr">119</xref>]. Psycho-educational interventions and medication reminders are thus important components of the holistic management approach to improve treatment adherence with psychotropic agents [<xref rid="B120-brainsci-14-00006" ref-type="bibr">120</xref>]. </p><p>High-dose AP prescription was found to be associated with several factors, such as male gender, inpatient treatment, and more severe psychopathology. Male patients and inpatients often exhibit greater aggressive behavior and more severe psychotic symptoms, which may need higher doses of APs for clinical management together with de-escalation strategies [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]. However, high-dose AP may increase the risk of side effects, such as EPSE, including neuroleptic malignant syndrome, thus care and close monitoring during administration is needed in clinical practice [<xref rid="B121-brainsci-14-00006" ref-type="bibr">121</xref>]. </p><p>The frequency of LAI use varied across different countries. The proportion of LAI prescriptions increased in Australia, but the use of LAI was limited in some other countries. LAIs have been associated with several clinical benefits, including better treatment adherence, reduced rates of relapse, hospitalizations, and decreased reliance on healthcare resources [<xref rid="B122-brainsci-14-00006" ref-type="bibr">122</xref>,<xref rid="B123-brainsci-14-00006" ref-type="bibr">123</xref>]. However, the proportion of LAI prescriptions is still low in many countries and possible reasons include availability and access to LAIs, high costs, especially with regard to second-generation LAIs, patient preference, clinician experience, and preference [<xref rid="B124-brainsci-14-00006" ref-type="bibr">124</xref>]. Further efforts can focus on addressing the abovementioned factors to improve the use of LAIs, and better engagement between clinicians and patients about risk&#8211;benefit discussions regarding the use of LAIs during treatment. </p><p>We found relatively high rates of APP across countries with rates up to 70% in some European countries. Of note, APP was associated with males, inpatient treatment settings, greater number of hospitalizations, more psychiatric comorbidities, and generally longer illness duration which suggested more severe and complex illness and with likely inadequate response to AP monotherapy. APP has been linked with EPSE and other adverse effects [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>], including weight gain [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>], and excessive sedation [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>] thus behooving greater attention and watchful clinical monitoring during treatment. Recent studies suggested that APP may be associated with longer periods of AP continuation [<xref rid="B125-brainsci-14-00006" ref-type="bibr">125</xref>] and reduced risk of hospitalization [<xref rid="B126-brainsci-14-00006" ref-type="bibr">126</xref>] but it is often not the first choice of treatment [<xref rid="B127-brainsci-14-00006" ref-type="bibr">127</xref>]. </p><p>The use of CLZ varied globally with rates ranging between 19% in Asia, 22.7% in Europe to 46% in the US. Within Asia, CLZ had limited usage in Japan, but it was commonly prescribed in China [<xref rid="B128-brainsci-14-00006" ref-type="bibr">128</xref>]. CLZ has only been available in Japan since 2009 [<xref rid="B128-brainsci-14-00006" ref-type="bibr">128</xref>]. Of late, there has been a reduction in the prescription of CLZ in China, due to the stringent treatment guidelines and greater availability of alternative and new AP [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]. CLZ has been proven to be effective over other APs for treatment-resistant schizophrenia [<xref rid="B129-brainsci-14-00006" ref-type="bibr">129</xref>,<xref rid="B130-brainsci-14-00006" ref-type="bibr">130</xref>], but it also has various side effects, including myocarditis, seizure, and agranulocytosis [<xref rid="B131-brainsci-14-00006" ref-type="bibr">131</xref>]. In view of better associated adherence and lower discontinuation rate [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B91-brainsci-14-00006" ref-type="bibr">91</xref>,<xref rid="B92-brainsci-14-00006" ref-type="bibr">92</xref>,<xref rid="B94-brainsci-14-00006" ref-type="bibr">94</xref>], the use of CLZ should be considered early for treatment refractory cases to allow for more expedient improvement of clinical status and functioning.</p><p>Over time, there was a general absolute rise in the prescription rates of adjunctive MS for schizophrenia patients. The use of MS was associated with numerous factors, such as longer duration of illness, APP, aggression, and suicidality, indicating more pronounced illness severity and less successful response to AP agents alone [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>]. MSs, such as valproate, have been found to reduce affective symptoms [<xref rid="B132-brainsci-14-00006" ref-type="bibr">132</xref>], aggression and hostility [<xref rid="B133-brainsci-14-00006" ref-type="bibr">133</xref>], and improve global symptoms in schizophrenia [<xref rid="B134-brainsci-14-00006" ref-type="bibr">134</xref>]. In addition, lithium, has both anti-suicidal and anti-aggressive properties, making it useful for the treatment of patients experiencing these distressing symptoms [<xref rid="B135-brainsci-14-00006" ref-type="bibr">135</xref>].</p><p>Adjunctive AD usage was noted to double over time in earlier studies and has been associated with a reduction in visits to the emergency department, psychiatric hospitalizations [<xref rid="B103-brainsci-14-00006" ref-type="bibr">103</xref>], and lower mortality [<xref rid="B36-brainsci-14-00006" ref-type="bibr">36</xref>]. Several factors were linked with adjunctive AD use, including female gender, outpatient treatment setting, and previous suicidality. Patients with schizophrenia reviewed in the outpatient context may have depressive symptoms, such as low mood and suicidality, especially females, thus necessitating the initiation of ADs in combination with APs. </p><sec><title>Practical Implications and Future Directions</title><p>Our review summarized extant global neuropsychopharmacological prescription trends in schizophrenia. The data help us understand the prescription trends over time, practice differences, and clinical correlates in the various geographical areas. There are several practical implications. First, by analyzing such psychotropic prescription patterns and clinical correlates, clinicians can identify patient profiles associated with specific medications and adverse effects. Second, it can raise awareness of local and global changes in the use of different psychotropic agents and prescription practices such as APP. This can increase awareness of prescription of excessive AP, and potentially lead to the simplification of the treatment regimen and reduction of side effects. Third, the prescription patterns of non-antipsychotic medications, such as ADs, MSs, and BZDs, help clinicians optimize the treatment of comorbid conditions or other symptoms among patients with schizophrenia. This can increase the overall clinical outcome and improve patient satisfaction. Lastly, the information in this review can contribute to refining psychotropic prescription practices and provide direction for future policymaking. </p><p>However, there are several limitations in this review. First, the sample size varied widely across different studies and smaller sample sizes may affect generalizability. Second, most studies are cross-sectional, so they may not be suitable for identifying probable causality between different clinical variables and prescription patterns. Third, there is heterogeneity in clinical assessment, diagnostic methods, and data collection across the studies. Fourth, only papers published in English were included in this review. Important prescription patterns described in articles that are published in other languages might be missed. </p><p>More research is needed in this area. Currently, the clinical correlates and outcomes associated with adjunctive medication use in schizophrenia, such as ADs and MSs, are not fully examined. More studies with larger cohorts can allow for such clinical comparisons of patients on such adjunctive medications versus not. It is also necessary to conduct cost-effectiveness analyses of different treatment options, including the long-term economic impact of various psychotropic drugs, so as to inform healthcare policies and resource allocation. Furthermore, given most current studies are cross-sectional, long-term prospective cohort studies are required to track the effects of different prescription patterns over time, including their impact on symptomatology, occurrence of side effects, and functional outcomes.</p><p>In conclusion, we found wide global variations in psychotropic prescription trends with an increase in the administration of SGA, MSs, and ADs and a decrease in the prescription rate of APP, high dose APs (up to 50% decrease in Asia), CLZ (up to 50% decrease) and LAIs. Further work, including more evidence in adjunctive neuropharmacological treatments, pharmaco-economic considerations, and examination of cohorts in longer prospective studies, can deepen understanding of changing prescription trends relevant to different treatment settings and predictors of such trends for enhancement of clinical management in schizophrenia. </p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-brainsci-14-00006"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/brainsci14010006/s1">https://www.mdpi.com/article/10.3390/brainsci14010006/s1</uri>, Table S1: Summary of details of all included studies in this review.</p><supplementary-material id="brainsci-14-00006-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="brainsci-14-00006-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.Y., Q.H.C., Y.W. and K.S.; methodology, J.Y., Q.H.C., Y.W. and K.S.; validation, J.Y., Q.H.C., Y.W. and K.S.; formal analysis, J.Y. and Q.H.C.; resources, J.Y. and Q.H.C.; data curation, J.Y. and Q.H.C.; writing&#8212;original draft preparation, J.Y. and Q.H.C.; writing&#8212;review and editing, J.Y., Q.H.C., Y.W. and K.S.; supervision, K.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>This is a literature review of previously published records, and all records are in the public domain. Summaries of the included records are provided in <xref rid="app1-brainsci-14-00006" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-brainsci-14-00006"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCutcheon</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Reis Marques</surname><given-names>T.</given-names></name><name name-style="western"><surname>Howes</surname><given-names>O.D.</given-names></name></person-group><article-title>Schizophrenia&#8212;An Overview</article-title><source>JAMA Psychiatry</source><year>2020</year><volume>77</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.3360</pub-id><pub-id pub-id-type="pmid">31664453</pub-id></element-citation></ref><ref id="B2-brainsci-14-00006"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlson</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Santomauro</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Diminic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stockings</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Whiteford</surname><given-names>H.A.</given-names></name></person-group><article-title>Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016</article-title><source>Schizophr. Bull.</source><year>2018</year><volume>44</volume><fpage>1195</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1093/schbul/sby058</pub-id><pub-id pub-id-type="pmid">29762765</pub-id><pub-id pub-id-type="pmcid">PMC6192504</pub-id></element-citation></ref><ref id="B3-brainsci-14-00006"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcus</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M.</given-names></name></person-group><article-title>Outpatient antipsychotic treatment and inpatient costs of schizophrenia</article-title><source>Schizophr. Bull.</source><year>2008</year><volume>34</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbm061</pub-id><pub-id pub-id-type="pmid">17578893</pub-id><pub-id pub-id-type="pmcid">PMC2632390</pub-id></element-citation></ref><ref id="B4-brainsci-14-00006"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangalore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>M.</given-names></name></person-group><article-title>Cost of schizophrenia in England</article-title><source>J. Ment. Health Policy Econ.</source><year>2007</year><volume>10</volume><fpage>23</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17417045</pub-id></element-citation></ref><ref id="B5-brainsci-14-00006"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>P.B.</given-names></name></person-group><article-title>Schizophrenia</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01121-6</pub-id><pub-id pub-id-type="pmid">26777917</pub-id><pub-id pub-id-type="pmcid">PMC4940219</pub-id></element-citation></ref><ref id="B6-brainsci-14-00006"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hagi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nitta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name></person-group><article-title>Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: A systematic review and meta-analysis of direct head-to-head comparisons</article-title><source>World Psychiatry</source><year>2019</year><volume>18</volume><fpage>208</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1002/wps.20632</pub-id><pub-id pub-id-type="pmid">31059621</pub-id><pub-id pub-id-type="pmcid">PMC6502423</pub-id></element-citation></ref><ref id="B7-brainsci-14-00006"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huhn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chaimani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mavridis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Helfer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Samara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabaioli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cipriani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors</article-title><source>Am. J. Psychiatry</source><year>2017</year><volume>174</volume><fpage>927</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2017.16121358</pub-id><pub-id pub-id-type="pmid">28541090</pub-id></element-citation></ref><ref id="B8-brainsci-14-00006"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tardy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komossa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kissling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name></person-group><article-title>Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>2063</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60239-6</pub-id><pub-id pub-id-type="pmid">22560607</pub-id></element-citation></ref><ref id="B9-brainsci-14-00006"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchanan</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kreyenbuhl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Boggs</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Himelhoch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements</article-title><source>Schizophr. Bull.</source><year>2010</year><volume>36</volume><fpage>71</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbp116</pub-id><pub-id pub-id-type="pmid">19955390</pub-id><pub-id pub-id-type="pmcid">PMC2800144</pub-id></element-citation></ref><ref id="B10-brainsci-14-00006"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.J.</given-names></name></person-group><article-title>New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1689</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18081689</pub-id><pub-id pub-id-type="pmid">28771182</pub-id><pub-id pub-id-type="pmcid">PMC5578079</pub-id></element-citation></ref><ref id="B11-brainsci-14-00006"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Grace</surname><given-names>A.A.</given-names></name></person-group><article-title>Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>4467</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094467</pub-id><pub-id pub-id-type="pmid">33922888</pub-id><pub-id pub-id-type="pmcid">PMC8123139</pub-id></element-citation></ref><ref id="B12-brainsci-14-00006"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Helfer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group><article-title>Valproate for schizophrenia</article-title><source>Cochrane Database Syst. Rev.</source><year>2016</year><volume>2016</volume><fpage>CD004028</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004028.pub4</pub-id><pub-id pub-id-type="pmid">27884042</pub-id><pub-id pub-id-type="pmcid">PMC6734130</pub-id></element-citation></ref><ref id="B13-brainsci-14-00006"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helfer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Samara</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Huhn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klupp</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group><article-title>Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis</article-title><source>Am. J. Psychiatry</source><year>2016</year><volume>173</volume><fpage>876</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2016.15081035</pub-id><pub-id pub-id-type="pmid">27282362</pub-id></element-citation></ref><ref id="B14-brainsci-14-00006"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machado-Vieira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manji</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Zarate</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis</article-title><source>Bipolar Disord.</source><year>2009</year><volume>11</volume><issue>(Suppl. 2)</issue><fpage>92</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2009.00714.x</pub-id><pub-id pub-id-type="pmid">19538689</pub-id><pub-id pub-id-type="pmcid">PMC2800957</pub-id></element-citation></ref><ref id="B15-brainsci-14-00006"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhi</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Tanious</surname><given-names>M.</given-names></name><name name-style="western"><surname>Das</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coulston</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>Potential mechanisms of action of lithium in bipolar disorder: Current understanding</article-title><source>CNS Drugs</source><year>2013</year><volume>27</volume><fpage>135</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/s40263-013-0039-0</pub-id><pub-id pub-id-type="pmid">23371914</pub-id></element-citation></ref><ref id="B16-brainsci-14-00006"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>S.I.</given-names></name></person-group><article-title>Mood-stabilizers target the brain arachidonic acid cascade</article-title><source>Curr. Mol. Pharmacol.</source><year>2009</year><volume>2</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.2174/1874467210902020207</pub-id><pub-id pub-id-type="pmid">20021459</pub-id><pub-id pub-id-type="pmcid">PMC2825027</pub-id></element-citation></ref><ref id="B17-brainsci-14-00006"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>I.</given-names></name></person-group><article-title>Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways</article-title><source>Cell. Signal.</source><year>2005</year><volume>17</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2004.12.007</pub-id><pub-id pub-id-type="pmid">15683730</pub-id><pub-id pub-id-type="pmcid">PMC3581018</pub-id></element-citation></ref><ref id="B18-brainsci-14-00006"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goff</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Freudenreich</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cather</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>I.</given-names></name><name name-style="western"><surname>Diminich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ardekani</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Worthington</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Citalopram in first episode schizophrenia: The DECIFER trial</article-title><source>Schizophr. Res.</source><year>2019</year><volume>208</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.01.028</pub-id><pub-id pub-id-type="pmid">30709746</pub-id></element-citation></ref><ref id="B19-brainsci-14-00006"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Najoan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kallivayalil</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Viboonma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jamaluddin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Javed</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey</article-title><source>Asian J. Psychiatr.</source><year>2019</year><volume>45</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ajp.2019.08.010</pub-id><pub-id pub-id-type="pmid">31520884</pub-id></element-citation></ref><ref id="B20-brainsci-14-00006"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lelliott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Okocha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duffett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sensky</surname><given-names>T.</given-names></name></person-group><article-title>The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK</article-title><source>Psychiatr. Bull.</source><year>2002</year><volume>26</volume><fpage>414</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1192/pb.26.11.414</pub-id></element-citation></ref><ref id="B21-brainsci-14-00006"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mimura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name></person-group><article-title>Antipsychotic polypharmacy: A Japanese survey of prescribers&#8217; attitudes and rationales</article-title><source>Psychiatry Res.</source><year>2013</year><volume>209</volume><fpage>406</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2013.03.014</pub-id><pub-id pub-id-type="pmid">23602697</pub-id><pub-id pub-id-type="pmcid">PMC3791180</pub-id></element-citation></ref><ref id="B22-brainsci-14-00006"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Depot antipsychotic use in schizophrenia: An East Asian perspective</article-title><source>Hum. Psychopharmacol.</source><year>2004</year><volume>19</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1002/hup.571</pub-id><pub-id pub-id-type="pmid">14994320</pub-id></element-citation></ref><ref id="B23-brainsci-14-00006"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Javed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.N.S.</given-names></name><name name-style="western"><surname>Grover</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prescription Patterns for Bipolar Disorder in Asian Countries: Findings from Research on Asian Prescription Pattern-Bipolar Disorder</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2022</year><volume>20</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.9758/cpn.2022.20.1.61</pub-id><pub-id pub-id-type="pmid">35078949</pub-id><pub-id pub-id-type="pmcid">PMC8813322</pub-id></element-citation></ref><ref id="B24-brainsci-14-00006"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arksey</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>L.</given-names></name></person-group><article-title>Scoping studies: Towards a methodological framework</article-title><source>Int. J. Soc. Res. Methodol.</source><year>2005</year><volume>8</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1080/1364557032000119616</pub-id></element-citation></ref><ref id="B25-brainsci-14-00006"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brostedt</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Msghina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wettermark</surname><given-names>B.</given-names></name></person-group><article-title>Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: A cross-sectional study</article-title><source>BMC Psychiatry</source><year>2017</year><volume>17</volume><elocation-id>416</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-017-1582-x</pub-id><pub-id pub-id-type="pmid">29284436</pub-id><pub-id pub-id-type="pmcid">PMC5747108</pub-id></element-citation></ref><ref id="B26-brainsci-14-00006"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DosReis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zito</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>A.F.</given-names></name></person-group><article-title>Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia</article-title><source>Schizophr. Bull.</source><year>2002</year><volume>28</volume><fpage>607</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a006968</pub-id><pub-id pub-id-type="pmid">12795494</pub-id></element-citation></ref><ref id="B27-brainsci-14-00006"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaviria</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Aguado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rico</surname><given-names>G.</given-names></name><name name-style="western"><surname>Labad</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Pablo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vilella</surname><given-names>E.</given-names></name></person-group><article-title>A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0139403</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0139403</pub-id><pub-id pub-id-type="pmid">26427051</pub-id><pub-id pub-id-type="pmcid">PMC4591292</pub-id></element-citation></ref><ref id="B28-brainsci-14-00006"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Antipsychotic patterns in outpatients with schizophrenia in China: A cross sectional study</article-title><source>Medicine</source><year>2021</year><volume>100</volume><fpage>e26912</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000026912</pub-id><pub-id pub-id-type="pmid">34397928</pub-id><pub-id pub-id-type="pmcid">PMC8360484</pub-id></element-citation></ref><ref id="B29-brainsci-14-00006"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanssens</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wampers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reginster</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Peuskens</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacological treatment of ambulatory schizophrenic patients in Belgium</article-title><source>Clin. Pract. Epidemiol. Ment. Health</source><year>2006</year><volume>2</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-2-11</pub-id><pub-id pub-id-type="pmid">16734909</pub-id><pub-id pub-id-type="pmcid">PMC1481604</pub-id></element-citation></ref><ref id="B30-brainsci-14-00006"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loosbrock</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>L.S.</given-names></name></person-group><article-title>Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia</article-title><source>J. Ment. Health Policy Econ.</source><year>2003</year><volume>6</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">14578539</pub-id></element-citation></ref><ref id="B31-brainsci-14-00006"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magliano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fiorillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guarneri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marasco</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malangone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maj</surname><given-names>M.</given-names></name><name name-style="western"><surname>National Mental Health Project Working</surname><given-names>G.</given-names></name></person-group><article-title>Prescription of psychotropic drugs to patients with schizophrenia: An Italian national survey</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2004</year><volume>60</volume><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s00228-004-0803-7</pub-id><pub-id pub-id-type="pmid">15316703</pub-id></element-citation></ref><ref id="B32-brainsci-14-00006"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mundt</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Aichberger</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Fakhriddinov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fayzirahmanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grohmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ivens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magzumova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sartorius</surname><given-names>N.</given-names></name><name name-style="western"><surname>Strohle</surname><given-names>A.</given-names></name></person-group><article-title>Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities</article-title><source>Pharmacoepidemiol. Drug Saf.</source><year>2012</year><volume>21</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/pds.2166</pub-id><pub-id pub-id-type="pmid">21726013</pub-id></element-citation></ref><ref id="B33-brainsci-14-00006"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olfson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>G.J.</given-names></name></person-group><article-title>Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients</article-title><source>Psychiatr. Serv.</source><year>2009</year><volume>60</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1176/ps.2009.60.2.210</pub-id><pub-id pub-id-type="pmid">19176415</pub-id></element-citation></ref><ref id="B34-brainsci-14-00006"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortiz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hollen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schacht</surname><given-names>L.</given-names></name></person-group><article-title>Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged from State Psychiatric Inpatient Hospitals</article-title><source>J. Psychiatr. Pract.</source><year>2016</year><volume>22</volume><fpage>283</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1097/PRA.0000000000000163</pub-id><pub-id pub-id-type="pmid">27427840</pub-id><pub-id pub-id-type="pmcid">PMC4956725</pub-id></element-citation></ref><ref id="B35-brainsci-14-00006"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Puranen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mittendorfer-Rutz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cervenka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lahteenvuo</surname><given-names>M.</given-names></name></person-group><article-title>Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences</article-title><source>Nord. J. Psychiatry</source><year>2021</year><volume>75</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1080/08039488.2020.1854853</pub-id><pub-id pub-id-type="pmid">33331804</pub-id></element-citation></ref><ref id="B36-brainsci-14-00006"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mittendorfer-Rutz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Torniainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alexanderson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name></person-group><article-title>Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients with Schizophrenia: An Observational Follow-Up Study</article-title><source>Am. J. Psychiatry</source><year>2016</year><volume>173</volume><fpage>600</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15050618</pub-id><pub-id pub-id-type="pmid">26651392</pub-id></element-citation></ref><ref id="B37-brainsci-14-00006"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsutsumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.</given-names></name><name name-style="western"><surname>Imasaka</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The evolution of antipsychotic switch and polypharmacy in natural practice&#8212;A longitudinal perspective</article-title><source>Schizophr. Res.</source><year>2011</year><volume>130</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2011.05.013</pub-id><pub-id pub-id-type="pmid">21624824</pub-id></element-citation></ref><ref id="B38-brainsci-14-00006"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001&#8211;2009)</article-title><source>Pharmacopsychiatry</source><year>2012</year><volume>45</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1286345</pub-id><pub-id pub-id-type="pmid">21989602</pub-id></element-citation></ref><ref id="B39-brainsci-14-00006"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadiei</surname><given-names>N.</given-names></name><name name-style="western"><surname>El-Ali</surname><given-names>J.</given-names></name><name name-style="western"><surname>Delaune</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.S.</given-names></name></person-group><article-title>Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia</article-title><source>Explor. Res. Clin. Soc. Pharm.</source><year>2022</year><volume>6</volume><fpage>100148</fpage><pub-id pub-id-type="doi">10.1016/j.rcsop.2022.100148</pub-id><pub-id pub-id-type="pmid">35755718</pub-id><pub-id pub-id-type="pmcid">PMC9218131</pub-id></element-citation></ref><ref id="B40-brainsci-14-00006"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wampers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peuskens</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacological treatment of hospitalised schizophrenic patients in Belgium</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2006</year><volume>10</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1080/13651500600811206</pub-id><pub-id pub-id-type="pmid">24941148</pub-id></element-citation></ref><ref id="B41-brainsci-14-00006"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>K.</given-names></name><name name-style="western"><surname>Isenberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>K.F.</given-names></name></person-group><article-title>Antipsychotic patterns of use in patients with schizophrenia: Polypharmacy versus monotherapy</article-title><source>BMC Psychiatry</source><year>2014</year><volume>14</volume><elocation-id>341</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-014-0341-5</pub-id><pub-id pub-id-type="pmid">25433495</pub-id><pub-id pub-id-type="pmcid">PMC4264319</pub-id></element-citation></ref><ref id="B42-brainsci-14-00006"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goren</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Meterko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Kilbourne</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M.S.</given-names></name></person-group><article-title>Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia</article-title><source>Psychiatr. Serv.</source><year>2013</year><volume>64</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.002022012</pub-id><pub-id pub-id-type="pmid">23450334</pub-id></element-citation></ref><ref id="B43-brainsci-14-00006"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>T.</given-names></name></person-group><article-title>The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan</article-title><source>J. Psychiatr. Res.</source><year>2020</year><volume>127</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2020.05.012</pub-id><pub-id pub-id-type="pmid">32450360</pub-id></element-citation></ref><ref id="B44-brainsci-14-00006"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichihashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Horai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project</article-title><source>Neuropsychopharmacol. Rep.</source><year>2020</year><volume>40</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1002/npr2.12122</pub-id><pub-id pub-id-type="pmid">32602667</pub-id><pub-id pub-id-type="pmcid">PMC7722678</pub-id></element-citation></ref><ref id="B45-brainsci-14-00006"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroken</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Johnsen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruud</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wentzel-Larsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>H.A.</given-names></name></person-group><article-title>Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study</article-title><source>BMC Psychiatry</source><year>2009</year><volume>9</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/1471-244X-9-24</pub-id><pub-id pub-id-type="pmid">19445700</pub-id><pub-id pub-id-type="pmcid">PMC2693495</pub-id></element-citation></ref><ref id="B46-brainsci-14-00006"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>P.X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.J.</given-names></name></person-group><article-title>Antipsychotic drug use in 503 Chinese inpatients with schizophrenia</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2007</year><volume>11</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1080/13651500600874360</pub-id><pub-id pub-id-type="pmid">24941273</pub-id></element-citation></ref><ref id="B47-brainsci-14-00006"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name></person-group><article-title>Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2018</year><volume>52</volume><fpage>1202</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1177/0004867418805559</pub-id><pub-id pub-id-type="pmid">30309245</pub-id></element-citation></ref><ref id="B48-brainsci-14-00006"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shenoy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amrtavarshini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhandary</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Praharaj</surname><given-names>S.K.</given-names></name></person-group><article-title>Frequency, reasons, and factors associated with antipsychotic polypharmacy in Schizophrenia: A retrospective chart review in a tertiary hospital in India</article-title><source>Asian J. Psychiatr.</source><year>2020</year><volume>51</volume><fpage>102022</fpage><pub-id pub-id-type="doi">10.1016/j.ajp.2020.102022</pub-id><pub-id pub-id-type="pmid">32278888</pub-id></element-citation></ref><ref id="B49-brainsci-14-00006"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Humberstone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>G.</given-names></name></person-group><article-title>Trends in antipsychotic prescribing in schizophrenia in Auckland</article-title><source>Australasian Psychiatry</source><year>2006</year><volume>14</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1080/j.1440-1665.2006.02273.x</pub-id><pub-id pub-id-type="pmid">16734645</pub-id></element-citation></ref><ref id="B50-brainsci-14-00006"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name></person-group><article-title>Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia</article-title><source>Pharmacopsychiatry</source><year>2007</year><volume>40</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1055/s-2007-970062</pub-id><pub-id pub-id-type="pmid">17447172</pub-id></element-citation></ref><ref id="B51-brainsci-14-00006"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamene</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Sema</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Sendekie</surname><given-names>A.K.</given-names></name></person-group><article-title>Antipsychotic polypharmacy and associated factors among patients with schizophrenia: Multicenter cross-sectional study in Northwest Ethiopia</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0290037</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0290037</pub-id><pub-id pub-id-type="pmid">37578965</pub-id><pub-id pub-id-type="pmcid">PMC10424862</pub-id></element-citation></ref><ref id="B52-brainsci-14-00006"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luthra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G.</given-names></name><name name-style="western"><surname>Luthra</surname><given-names>N.</given-names></name></person-group><article-title>Prevalence of High-dose Antipsychotic Prescribing in Schizophrenia: A Clinical Audit in a Regional Queensland Mental Health Service</article-title><source>Int. J. Appl. Basic Med. Res.</source><year>2023</year><volume>13</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.4103/ijabmr.ijabmr_504_22</pub-id><pub-id pub-id-type="pmid">37614838</pub-id><pub-id pub-id-type="pmcid">PMC10443448</pub-id></element-citation></ref><ref id="B53-brainsci-14-00006"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faries</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ascher-Svanum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.</given-names></name></person-group><article-title>Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics</article-title><source>BMC Psychiatry</source><year>2005</year><volume>5</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/1471-244X-5-26</pub-id><pub-id pub-id-type="pmid">15921508</pub-id><pub-id pub-id-type="pmcid">PMC1156914</pub-id></element-citation></ref><ref id="B54-brainsci-14-00006"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igbinomwanhia</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Olotu</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>James</surname><given-names>B.O.</given-names></name></person-group><article-title>Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2017</year><volume>7</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1177/2045125316672134</pub-id><pub-id pub-id-type="pmid">28101318</pub-id><pub-id pub-id-type="pmcid">PMC5228713</pub-id></element-citation></ref><ref id="B55-brainsci-14-00006"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name></person-group><article-title>Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006</article-title><source>Pharmacoepidemiol. Drug Saf.</source><year>2012</year><volume>21</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1002/pds.3254</pub-id><pub-id pub-id-type="pmid">22416032</pub-id></element-citation></ref><ref id="B56-brainsci-14-00006"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miron</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Petric</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Teodorescu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ifteni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chele</surname><given-names>G.</given-names></name><name name-style="western"><surname>Szalontay</surname><given-names>A.S.</given-names></name></person-group><article-title>Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study</article-title><source>Brain Sci.</source><year>2023</year><volume>13</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci13020173</pub-id><pub-id pub-id-type="pmid">36831716</pub-id><pub-id pub-id-type="pmcid">PMC9953951</pub-id></element-citation></ref><ref id="B57-brainsci-14-00006"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>T.</given-names></name><name name-style="western"><surname>Christova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>G.</given-names></name><name name-style="western"><surname>McKendrick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laugharne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Obuaya</surname><given-names>T.</given-names></name><name name-style="western"><surname>McCreadie</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perrington</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: A naturalistic cohort study</article-title><source>Acta Psychiatr. Scand.</source><year>2006</year><volume>113</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2005.00622.x</pub-id><pub-id pub-id-type="pmid">16423164</pub-id></element-citation></ref><ref id="B58-brainsci-14-00006"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gamon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hurtado</surname><given-names>I.</given-names></name><name name-style="western"><surname>Salazar-Fraile</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanfelix-Gimeno</surname><given-names>G.</given-names></name></person-group><article-title>Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>13509</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-92731-w</pub-id><pub-id pub-id-type="pmid">34188093</pub-id><pub-id pub-id-type="pmcid">PMC8241998</pub-id></element-citation></ref><ref id="B59-brainsci-14-00006"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothbard</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>K.</given-names></name></person-group><article-title>Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia</article-title><source>Schizophr. Bull.</source><year>2003</year><volume>29</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a007025</pub-id><pub-id pub-id-type="pmid">14609246</pub-id></element-citation></ref><ref id="B60-brainsci-14-00006"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesfaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debencho</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kisi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tareke</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia</article-title><source>Psychiatry J.</source><year>2016</year><volume>2016</volume><fpage>6191074</fpage><pub-id pub-id-type="doi">10.1155/2016/6191074</pub-id><pub-id pub-id-type="pmid">26904586</pub-id><pub-id pub-id-type="pmcid">PMC4745389</pub-id></element-citation></ref><ref id="B61-brainsci-14-00006"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sathian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A.</given-names></name></person-group><article-title>Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: A cross sectional study from western region of Nepal</article-title><source>BMC Psychiatry</source><year>2013</year><volume>13</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.1186/1471-244X-13-96</pub-id><pub-id pub-id-type="pmid">23522357</pub-id><pub-id pub-id-type="pmcid">PMC4103665</pub-id></element-citation></ref><ref id="B62-brainsci-14-00006"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De las Cuevas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>E.J.</given-names></name></person-group><article-title>Polypharmacy in psychiatric practice in the Canary Islands</article-title><source>BMC Psychiatry</source><year>2004</year><volume>4</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/1471-244X-4-18</pub-id><pub-id pub-id-type="pmid">15236661</pub-id><pub-id pub-id-type="pmcid">PMC471555</pub-id></element-citation></ref><ref id="B63-brainsci-14-00006"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2015</year><volume>49</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1177/0004867414536931</pub-id><pub-id pub-id-type="pmid">24923760</pub-id></element-citation></ref><ref id="B64-brainsci-14-00006"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.H.</given-names></name><etal/></person-group><article-title>Adjunctive antidepressant use in schizophrenia in China: A national survey (2002&#8211;2012)</article-title><source>Hum. Psychopharmacol.</source><year>2017</year><volume>32</volume><fpage>e2571</fpage><pub-id pub-id-type="doi">10.1002/hup.2571</pub-id><pub-id pub-id-type="pmid">28120487</pub-id></element-citation></ref><ref id="B65-brainsci-14-00006"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kanba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shinfuku</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study</article-title><source>Hum. Psychopharmacol.</source><year>2020</year><volume>35</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/hup.2752</pub-id><pub-id pub-id-type="pmid">32738085</pub-id></element-citation></ref><ref id="B66-brainsci-14-00006"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Bond</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Tunis</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>M.L.</given-names></name></person-group><article-title>Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program</article-title><source>J. Clin. Psychiatry</source><year>2002</year><volume>63</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.4088/JCP.v63n0204</pub-id><pub-id pub-id-type="pmid">11874210</pub-id></element-citation></ref><ref id="B67-brainsci-14-00006"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirakawa</surname><given-names>J.</given-names></name></person-group><article-title>Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study</article-title><source>Schizophr. Res.</source><year>2010</year><volume>119</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2010.02.1061</pub-id><pub-id pub-id-type="pmid">20304611</pub-id></element-citation></ref><ref id="B68-brainsci-14-00006"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>High-dose antipsychotic use in schizophrenia: A comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies</article-title><source>Br. J. Clin. Pharmacol.</source><year>2009</year><volume>67</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03304.x</pub-id><pub-id pub-id-type="pmid">19133060</pub-id><pub-id pub-id-type="pmcid">PMC2668091</pub-id></element-citation></ref><ref id="B69-brainsci-14-00006"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Tor</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001&#8211;2008)</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2011</year><volume>14</volume><fpage>1157</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1017/S1461145711000563</pub-id><pub-id pub-id-type="pmid">21557883</pub-id></element-citation></ref><ref id="B70-brainsci-14-00006"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001&#8211;2009)</article-title><source>Asia Pac. Psychiatry</source><year>2013</year><volume>5</volume><fpage>E81</fpage><lpage>E87</lpage><pub-id pub-id-type="doi">10.1111/j.1758-5872.2012.00231.x</pub-id><pub-id pub-id-type="pmid">23857816</pub-id></element-citation></ref><ref id="B71-brainsci-14-00006"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>W.J.</given-names></name></person-group><article-title>Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy</article-title><source>Schizophr. Bull.</source><year>2002</year><volume>28</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a006928</pub-id><pub-id pub-id-type="pmid">12047024</pub-id></element-citation></ref><ref id="B72-brainsci-14-00006"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davids</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bunk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Specka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gastpar</surname><given-names>M.</given-names></name></person-group><article-title>Psychotropic drug prescription in a psychiatric university hospital in Germany</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2006</year><volume>30</volume><fpage>1109</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.04.015</pub-id><pub-id pub-id-type="pmid">16737763</pub-id></element-citation></ref><ref id="B73-brainsci-14-00006"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>le Quach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Emborg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Foldager</surname><given-names>L.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name></person-group><article-title>10-year trends in the treatment and outcomes of patients with first-episode schizophrenia</article-title><source>Acta Psychiatr. Scand.</source><year>2010</year><volume>122</volume><fpage>356</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2010.01576.x</pub-id><pub-id pub-id-type="pmid">20528803</pub-id></element-citation></ref><ref id="B74-brainsci-14-00006"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Fung-Shing</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name></person-group><article-title>The pharmacological treatment of schizophrenia in Chinese patients: A comparison of prescription patterns between 1996 and 1999</article-title><source>Br. J. Clin. Pharmacol.</source><year>2002</year><volume>54</volume><fpage>437</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01668.x</pub-id><pub-id pub-id-type="pmid">12392594</pub-id><pub-id pub-id-type="pmcid">PMC1874444</pub-id></element-citation></ref><ref id="B75-brainsci-14-00006"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.C.</given-names></name></person-group><article-title>Antipsychotic polypharmacy and high-dose prescription in schizophrenia: A 5-year comparison</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2014</year><volume>48</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/0004867413488221</pub-id><pub-id pub-id-type="pmid">23671214</pub-id></element-citation></ref><ref id="B76-brainsci-14-00006"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasrallah</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Csoboth</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Julian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lentz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nuechterlein</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Kotowsky</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization</article-title><source>Schizophr. Res.</source><year>2015</year><volume>166</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2015.04.031</pub-id><pub-id pub-id-type="pmid">26027848</pub-id></element-citation></ref><ref id="B77-brainsci-14-00006"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anozie</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>James</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Omoaregba</surname><given-names>J.O.</given-names></name></person-group><article-title>Antipsychotic prescription and polypharmacy among outpatients with schizophrenia in a Nigerian hospital</article-title><source>Niger. Postgrad. Med. J.</source><year>2020</year><volume>27</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.4103/npmj.npmj_93_19</pub-id><pub-id pub-id-type="pmid">32003359</pub-id></element-citation></ref><ref id="B78-brainsci-14-00006"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Megna</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kunwar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mahlotra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sauro</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Devitt</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>A.</given-names></name></person-group><article-title>A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness</article-title><source>J. Psychiatr. Pract.</source><year>2007</year><volume>13</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1097/01.pra.0000265773.03756.3e</pub-id><pub-id pub-id-type="pmid">17414692</pub-id></element-citation></ref><ref id="B79-brainsci-14-00006"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bousono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Olivares</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Montejo</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Haro</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Edgell</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Ratcliffe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Board</surname><given-names>S.A.</given-names></name></person-group><article-title>Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2005</year><volume>29</volume><fpage>972</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.06.003</pub-id><pub-id pub-id-type="pmid">16023776</pub-id></element-citation></ref><ref id="B80-brainsci-14-00006"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hausmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kemmler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurzthaler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Walch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Walpoth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fleischhacker</surname><given-names>W.W.</given-names></name></person-group><article-title>Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period</article-title><source>Schizophr. Res.</source><year>2005</year><volume>77</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.01.015</pub-id><pub-id pub-id-type="pmid">16005382</pub-id></element-citation></ref><ref id="B81-brainsci-14-00006"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heald</surname><given-names>A.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.A.</given-names></name></person-group><article-title>Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time</article-title><source>Hum. Psychopharmacol.</source><year>2017</year><volume>32</volume><fpage>e2579</fpage><pub-id pub-id-type="doi">10.1002/hup.2579</pub-id><pub-id pub-id-type="pmid">28370308</pub-id></element-citation></ref><ref id="B82-brainsci-14-00006"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fulone</surname><given-names>I.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>L.C.</given-names></name></person-group><article-title>Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: A cohort study, 2008&#8211;2017</article-title><source>Epidemiol. Serv. Saude</source><year>2023</year><volume>32</volume><fpage>e2022556</fpage><pub-id pub-id-type="doi">10.1590/S2237-96222023000300015</pub-id><pub-id pub-id-type="pmid">36946832</pub-id><pub-id pub-id-type="pmcid">PMC10072313</pub-id></element-citation></ref><ref id="B83-brainsci-14-00006"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reist</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Montejano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lenhart</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cuffel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harnett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>K.N.</given-names></name></person-group><article-title>Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder</article-title><source>Schizophr. Res.</source><year>2009</year><volume>108</volume><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2008.11.017</pub-id><pub-id pub-id-type="pmid">19106035</pub-id></element-citation></ref><ref id="B84-brainsci-14-00006"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L.</given-names></name></person-group><article-title>Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: A cross-sectional study</article-title><source>Int. Clin. Psychopharmacol.</source><year>2014</year><volume>29</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1097/YIC.0000000000000024</pub-id><pub-id pub-id-type="pmid">24323200</pub-id></element-citation></ref><ref id="B85-brainsci-14-00006"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fond</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Favez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brunel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aouizerate</surname><given-names>B.</given-names></name><name name-style="western"><surname>Berna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Capdevielle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chereau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dorey</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dubertret</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset</article-title><source>Psychopharmacology</source><year>2016</year><volume>233</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1007/s00213-015-4167-8</pub-id><pub-id pub-id-type="pmid">26630993</pub-id></element-citation></ref><ref id="B86-brainsci-14-00006"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yasui-Furukori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iga</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Ochi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ichihashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furihata</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kyo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takaesu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Prescription of Anticholinergic Drugs in Patients with Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics</article-title><source>Front. Psychiatry</source><year>2022</year><volume>13</volume><elocation-id>823826</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2022.823826</pub-id><pub-id pub-id-type="pmid">35656353</pub-id><pub-id pub-id-type="pmcid">PMC9152135</pub-id></element-citation></ref><ref id="B87-brainsci-14-00006"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otsubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kunisawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Imanaka</surname><given-names>Y.</given-names></name></person-group><article-title>Factors associated with high-dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture</article-title><source>Neuropsychopharmacol. Rep.</source><year>2020</year><volume>40</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1002/npr2.12109</pub-id><pub-id pub-id-type="pmid">32452649</pub-id><pub-id pub-id-type="pmcid">PMC7722669</pub-id></element-citation></ref><ref id="B88-brainsci-14-00006"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name></person-group><article-title>Long-term use of mood stabilizers and its impact on the quality of life of chinese patients with schizophrenia</article-title><source>Clin. Neuropharmacol.</source><year>2009</year><volume>32</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e31815d25b5</pub-id><pub-id pub-id-type="pmid">18978504</pub-id></element-citation></ref><ref id="B89-brainsci-14-00006"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anozie</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>James</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Omoaregba</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Oriji</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Erohubie</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Enebe</surname><given-names>A.C.</given-names></name></person-group><article-title>Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital</article-title><source>S. Afr. J. Psychiatr.</source><year>2022</year><volume>28</volume><fpage>1791</fpage><pub-id pub-id-type="doi">10.4102/sajpsychiatry.v28i0.1791</pub-id><pub-id pub-id-type="pmid">35547105</pub-id><pub-id pub-id-type="pmcid">PMC9082254</pub-id></element-citation></ref><ref id="B90-brainsci-14-00006"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.K.</given-names></name><etal/></person-group><article-title>High dose antipsychotic use in schizophrenia: Findings of the REAP (research on east Asia psychotropic prescriptions) study</article-title><source>Pharmacopsychiatry</source><year>2004</year><volume>37</volume><fpage>175</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1055/s-2004-827174</pub-id><pub-id pub-id-type="pmid">15467975</pub-id></element-citation></ref><ref id="B91-brainsci-14-00006"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Belgamwar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-tawarah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>MacKenzie</surname><given-names>G.</given-names></name></person-group><article-title>The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire</article-title><source>Hum. Psychopharmacol.</source><year>2005</year><volume>20</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1002/hup.669</pub-id><pub-id pub-id-type="pmid">15651052</pub-id></element-citation></ref><ref id="B92-brainsci-14-00006"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Acar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Juneja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kouhkamari</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Siva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mullan</surname><given-names>J.</given-names></name></person-group><article-title>Antipsychotic prescribing patterns in Australia: A retrospective analysis</article-title><source>BMC Psychiatry</source><year>2022</year><volume>22</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-022-03755-z</pub-id><pub-id pub-id-type="pmid">35148707</pub-id><pub-id pub-id-type="pmcid">PMC8840322</pub-id></element-citation></ref><ref id="B93-brainsci-14-00006"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sultana</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hurtado</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bejarano-Quisoboni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giorgianni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huybrechts</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Patorno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sanf&#233;lix-Gimeno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tari</surname><given-names>D.U.</given-names></name><name name-style="western"><surname>Trifir&#242;</surname><given-names>G.</given-names></name></person-group><article-title>Antipsychotic utilization patterns among patients with schizophrenic disorder: A cross-national analysis in four countries</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2019</year><volume>75</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1007/s00228-019-02654-9</pub-id><pub-id pub-id-type="pmid">30824947</pub-id></element-citation></ref><ref id="B94-brainsci-14-00006"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haro</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Novick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P.B.</given-names></name></person-group><article-title>Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia</article-title><source>Eur. Psychiatry</source><year>2006</year><volume>21</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2005.12.001</pub-id><pub-id pub-id-type="pmid">16414249</pub-id></element-citation></ref><ref id="B95-brainsci-14-00006"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DosReis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steinwachs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fahey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>A.F.</given-names></name></person-group><article-title>Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia</article-title><source>Schizophr. Res.</source><year>2008</year><volume>101</volume><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2007.12.475</pub-id><pub-id pub-id-type="pmid">18255270</pub-id><pub-id pub-id-type="pmcid">PMC3255481</pub-id></element-citation></ref><ref id="B96-brainsci-14-00006"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fond</surname><given-names>G.</given-names></name><name name-style="western"><surname>Falissard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nuss</surname><given-names>P.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duret</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rabbani</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Chefdebien</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Llorca</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>L.</given-names></name></person-group><article-title>How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients</article-title><source>Mol. Psychiatry</source><year>2023</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02154-4</pub-id><pub-id pub-id-type="pmcid">PMC11041650</pub-id><pub-id pub-id-type="pmid">37479782</pub-id></element-citation></ref><ref id="B97-brainsci-14-00006"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lachaine</surname><given-names>J.</given-names></name></person-group><article-title>Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2018</year><volume>8</volume><fpage>287</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1177/2045125318782694</pub-id><pub-id pub-id-type="pmid">30344996</pub-id><pub-id pub-id-type="pmcid">PMC6180377</pub-id></element-citation></ref><ref id="B98-brainsci-14-00006"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ascher-Svanum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Faries</surname><given-names>D.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>W.</given-names></name><name name-style="western"><surname>Marder</surname><given-names>S.R.</given-names></name></person-group><article-title>Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia</article-title><source>Psychiatr. Serv.</source><year>2007</year><volume>58</volume><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1176/ps.2007.58.4.482</pub-id><pub-id pub-id-type="pmid">17412849</pub-id></element-citation></ref><ref id="B99-brainsci-14-00006"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontanella</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hiance-Steelesmith</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Guirgis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Campo</surname><given-names>J.V.</given-names></name></person-group><article-title>Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008&#8211;2014</article-title><source>Psychiatr. Serv.</source><year>2018</year><volume>69</volume><fpage>1015</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.201800052</pub-id><pub-id pub-id-type="pmid">29962308</pub-id></element-citation></ref><ref id="B100-brainsci-14-00006"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kotzan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.C.</given-names></name></person-group><article-title>Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998&#8211;2000</article-title><source>J. Clin. Psychiatry</source><year>2004</year><volume>65</volume><fpage>1377</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.4088/JCP.v65n1013</pub-id><pub-id pub-id-type="pmid">15491242</pub-id></element-citation></ref><ref id="B101-brainsci-14-00006"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreyenbuhl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valenstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ganoczy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blow</surname><given-names>F.C.</given-names></name></person-group><article-title>Long-term combination antipsychotic treatment in VA patients with schizophrenia</article-title><source>Schizophr. Res.</source><year>2006</year><volume>84</volume><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2006.02.023</pub-id><pub-id pub-id-type="pmid">16631354</pub-id></element-citation></ref><ref id="B102-brainsci-14-00006"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreyenbuhl</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Valenstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ganoczy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blow</surname><given-names>F.C.</given-names></name></person-group><article-title>Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns</article-title><source>Psychiatr. Serv.</source><year>2007</year><volume>58</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1176/ps.2007.58.4.489</pub-id><pub-id pub-id-type="pmid">17412850</pub-id><pub-id pub-id-type="pmcid">PMC3673552</pub-id></element-citation></ref><ref id="B103-brainsci-14-00006"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroup</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Gerhard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mathai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M.</given-names></name></person-group><article-title>Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients with Schizophrenia</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.4489</pub-id><pub-id pub-id-type="pmid">30785609</pub-id><pub-id pub-id-type="pmcid">PMC6495353</pub-id></element-citation></ref><ref id="B104-brainsci-14-00006"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sneider</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pristed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>J.</given-names></name></person-group><article-title>Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study</article-title><source>Eur. Neuropsychopharmacol.</source><year>2015</year><volume>25</volume><fpage>1669</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.04.027</pub-id><pub-id pub-id-type="pmid">26256007</pub-id></element-citation></ref><ref id="B105-brainsci-14-00006"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia</article-title><source>Br. J. Clin. Pharmacol.</source><year>2004</year><volume>58</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2004.02102.x</pub-id><pub-id pub-id-type="pmid">15255800</pub-id><pub-id pub-id-type="pmcid">PMC1884580</pub-id></element-citation></ref><ref id="B106-brainsci-14-00006"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Horvitz-Lennon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gellad</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Lave</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Normand</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>J.M.</given-names></name></person-group><article-title>Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program</article-title><source>Psychiatr. Serv.</source><year>2017</year><volume>68</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.201600041</pub-id><pub-id pub-id-type="pmid">28196460</pub-id></element-citation></ref><ref id="B107-brainsci-14-00006"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagreula</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Timary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dalleur</surname><given-names>O.</given-names></name></person-group><article-title>Antipsychotic polypharmacy and clozapine prescribing patterns: Evolution and correlates before and after a psychiatric hospitalisation</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2022</year><volume>12</volume><fpage>20451253221112587</fpage><pub-id pub-id-type="doi">10.1177/20451253221112587</pub-id><pub-id pub-id-type="pmid">36051501</pub-id><pub-id pub-id-type="pmcid">PMC9425880</pub-id></element-citation></ref><ref id="B108-brainsci-14-00006"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaudiano</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Guzman Holst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sydnor</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Epstein-Lubow</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>L.M.</given-names></name></person-group><article-title>Complex Polypharmacy in Patients with Schizophrenia-Spectrum Disorders Before a Psychiatric Hospitalization: Prescribing Patterns and Associated Clinical Features</article-title><source>J. Clin. Psychopharmacol.</source><year>2018</year><volume>38</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000876</pub-id><pub-id pub-id-type="pmid">29620698</pub-id></element-citation></ref><ref id="B109-brainsci-14-00006"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Dorfman</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Fincham</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.C.</given-names></name></person-group><article-title>The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia</article-title><source>Curr. Med. Res. Opin.</source><year>2007</year><volume>23</volume><fpage>1351</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1185/030079907X187883</pub-id><pub-id pub-id-type="pmid">17559734</pub-id></element-citation></ref><ref id="B110-brainsci-14-00006"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puranen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koponen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taipale</surname><given-names>H.</given-names></name></person-group><article-title>Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2020</year><volume>76</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-02830-2</pub-id><pub-id pub-id-type="pmid">31940085</pub-id></element-citation></ref><ref id="B111-brainsci-14-00006"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Himelhoch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Slade</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kreyenbuhl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Medoff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>L.</given-names></name></person-group><article-title>Antidepressant prescribing patterns among VA patients with schizophrenia</article-title><source>Schizophr. Res.</source><year>2012</year><volume>136</volume><fpage>32</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2012.01.008</pub-id><pub-id pub-id-type="pmid">22325077</pub-id></element-citation></ref><ref id="B112-brainsci-14-00006"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Toward convergence in the medication treatment of bipolar disorder and schizophrenia</article-title><source>Harv. Rev. Psychiatry</source><year>2005</year><volume>13</volume><fpage>28</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/10673220590923164</pub-id><pub-id pub-id-type="pmid">15804932</pub-id></element-citation></ref><ref id="B113-brainsci-14-00006"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corves</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arbter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name></person-group><article-title>Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61764-X</pub-id><pub-id pub-id-type="pmid">19058842</pub-id></element-citation></ref><ref id="B114-brainsci-14-00006"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Chiles</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Conley</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Crismon</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Essock</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Finnerty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marder</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.D.</given-names></name><etal/></person-group><article-title>The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update</article-title><source>J. Clin. Psychiatry</source><year>2007</year><volume>68</volume><fpage>1751</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n1115</pub-id><pub-id pub-id-type="pmid">18052569</pub-id></element-citation></ref><ref id="B115-brainsci-14-00006"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huhn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schneider-Thoma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arndt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Backers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rothe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cipriani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>939</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31135-3</pub-id><pub-id pub-id-type="pmid">31303314</pub-id><pub-id pub-id-type="pmcid">PMC6891890</pub-id></element-citation></ref><ref id="B116-brainsci-14-00006"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rummel-Kluge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Komossa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hunger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lobos</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Kissling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group><article-title>Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis</article-title><source>Schizophr. Res.</source><year>2010</year><volume>123</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2010.07.012</pub-id><pub-id pub-id-type="pmid">20692814</pub-id><pub-id pub-id-type="pmcid">PMC2957510</pub-id></element-citation></ref><ref id="B117-brainsci-14-00006"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Medic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Littlewood</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Diez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Granstrom</surname><given-names>O.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name></person-group><article-title>Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2013</year><volume>3</volume><fpage>200</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1177/2045125312474019</pub-id><pub-id pub-id-type="pmid">24167693</pub-id><pub-id pub-id-type="pmcid">PMC3805432</pub-id></element-citation></ref><ref id="B118-brainsci-14-00006"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>W.</given-names></name></person-group><article-title>Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization</article-title><source>Pharmacotherapy</source><year>2015</year><volume>35</volume><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1002/phar.1634</pub-id><pub-id pub-id-type="pmid">26406773</pub-id></element-citation></ref><ref id="B119-brainsci-14-00006"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceraso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Schneider-Thoma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siafis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kissling</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group><article-title>Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis</article-title><source>Schizophr. Bull.</source><year>2022</year><volume>48</volume><fpage>738</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbac041</pub-id><pub-id pub-id-type="pmid">35556140</pub-id><pub-id pub-id-type="pmcid">PMC9212092</pub-id></element-citation></ref><ref id="B120-brainsci-14-00006"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giardini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Savin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Menditto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lehane</surname><given-names>E.</given-names></name><name name-style="western"><surname>Laosa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pecorelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monaco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marengoni</surname><given-names>A.</given-names></name></person-group><article-title>Interventional tools to improve medication adherence: Review of literature</article-title><source>Patient Prefer. Adherence</source><year>2015</year><volume>9</volume><fpage>1303</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.2147/PPA.S87551</pub-id><pub-id pub-id-type="pmid">26396502</pub-id><pub-id pub-id-type="pmcid">PMC4576894</pub-id></element-citation></ref><ref id="B121-brainsci-14-00006"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Centorrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>International consensus study of antipsychotic dosing</article-title><source>Am. J. Psychiatry</source><year>2010</year><volume>167</volume><fpage>686</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09060802</pub-id><pub-id pub-id-type="pmid">20360319</pub-id></element-citation></ref><ref id="B122-brainsci-14-00006"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zummo</surname><given-names>J.</given-names></name></person-group><article-title>Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia</article-title><source>Early Interv. Psychiatry</source><year>2016</year><volume>10</volume><fpage>365</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1111/eip.12278</pub-id><pub-id pub-id-type="pmid">26403538</pub-id><pub-id pub-id-type="pmcid">PMC5054869</pub-id></element-citation></ref><ref id="B123-brainsci-14-00006"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Procyshyn</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Fredrikson</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Cazares</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honer</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>A.M.</given-names></name></person-group><article-title>Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis</article-title><source>Early Interv. Psychiatry</source><year>2022</year><volume>16</volume><fpage>589</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1111/eip.13202</pub-id><pub-id pub-id-type="pmid">34263540</pub-id></element-citation></ref><ref id="B124-brainsci-14-00006"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pesa</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Muser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montejano</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>O.I.</given-names></name></person-group><article-title>Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics</article-title><source>Drugs Real World Outcomes</source><year>2015</year><volume>2</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s40801-015-0043-4</pub-id><pub-id pub-id-type="pmid">26689953</pub-id><pub-id pub-id-type="pmcid">PMC4674518</pub-id></element-citation></ref><ref id="B125-brainsci-14-00006"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Slade</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Medoff</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kreyenbuhl</surname><given-names>J.</given-names></name></person-group><article-title>Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs</article-title><source>Am. J. Psychiatry</source><year>2021</year><volume>178</volume><fpage>932</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20111657</pub-id><pub-id pub-id-type="pmid">34256606</pub-id></element-citation></ref><ref id="B126-brainsci-14-00006"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name></person-group><article-title>Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients with Schizophrenia</article-title><source>Am. J. Psychiatry</source><year>2023</year><volume>180</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.20220446</pub-id><pub-id pub-id-type="pmid">36945825</pub-id></element-citation></ref><ref id="B127-brainsci-14-00006"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Rummel-Kluge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corves</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group><article-title>Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials</article-title><source>Schizophr. Bull.</source><year>2009</year><volume>35</volume><fpage>443</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbn018</pub-id><pub-id pub-id-type="pmid">18417466</pub-id><pub-id pub-id-type="pmcid">PMC2659301</pub-id></element-citation></ref><ref id="B128-brainsci-14-00006"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Si</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Shinfuku</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Clozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2011</year><volume>45</volume><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.3109/00048674.2011.607426</pub-id><pub-id pub-id-type="pmid">21888603</pub-id></element-citation></ref><ref id="B129-brainsci-14-00006"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahlbeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Essali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>C.</given-names></name></person-group><article-title>Evidence of clozapine&#8217;s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials</article-title><source>Am. J. Psychiatry</source><year>1999</year><volume>156</volume><fpage>990</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1176/ajp.156.7.990</pub-id><pub-id pub-id-type="pmid">10401441</pub-id></element-citation></ref><ref id="B130-brainsci-14-00006"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheitman</surname><given-names>B.</given-names></name></person-group><article-title>Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials</article-title><source>Am. J. Psychiatry</source><year>2001</year><volume>158</volume><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.158.4.518</pub-id><pub-id pub-id-type="pmid">11282684</pub-id></element-citation></ref><ref id="B131-brainsci-14-00006"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Freudenreich</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sayer</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Love</surname><given-names>R.C.</given-names></name></person-group><article-title>Addressing Barriers to Clozapine Underutilization: A National Effort</article-title><source>Psychiatr. Serv.</source><year>2018</year><volume>69</volume><fpage>224</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.201700162</pub-id><pub-id pub-id-type="pmid">29032704</pub-id><pub-id pub-id-type="pmcid">PMC8581998</pub-id></element-citation></ref><ref id="B132-brainsci-14-00006"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Di Lieto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Auvinen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>D.</given-names></name></person-group><article-title>Re-analysis of bipolar disorder and schizophrenia gene expression complements the Kraepelinian dichotomy</article-title><source>Adv. Exp. Med. Biol.</source><year>2012</year><volume>736</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">22161352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4419-7210-1_33</pub-id></element-citation></ref><ref id="B133-brainsci-14-00006"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kochan</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>K.A.</given-names></name></person-group><article-title>Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone</article-title><source>Psychiatr. Serv.</source><year>2004</year><volume>55</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.55.3.290</pub-id><pub-id pub-id-type="pmid">15001730</pub-id></element-citation></ref><ref id="B134-brainsci-14-00006"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Conley</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>C.M.</given-names></name></person-group><article-title>Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia</article-title><source>Psychiatr. Q.</source><year>2006</year><volume>77</volume><fpage>81</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s11126-006-7963-9</pub-id><pub-id pub-id-type="pmid">16397757</pub-id></element-citation></ref><ref id="B135-brainsci-14-00006"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller-Oerlinghausen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lewitzka</surname><given-names>U.</given-names></name></person-group><article-title>Lithium reduces pathological aggression and suicidality: A mini-review</article-title><source>Neuropsychobiology</source><year>2010</year><volume>62</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1159/000314309</pub-id><pub-id pub-id-type="pmid">20453534</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="brainsci-14-00006-f001" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flowchart of the study selection process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="brainsci-14-00006-g001.jpg"/></fig><table-wrap position="float" id="brainsci-14-00006-t001" orientation="portrait"><object-id pub-id-type="pii">brainsci-14-00006-t001_Table 1</object-id><label>Table 1</label><caption><p>High-dose antipsychotic prescription and clinical correlates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Increased Frequency of High-Dose Antipsychotic Prescription</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Decreased <break/> Frequency of High-Dose Antipsychotic Prescription</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Socio-demographic factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Being male [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>] <break/> Being Indigenous Australians [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Older age [<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Treatment factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Higher monthly cost of medications [<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of second-generation antipsychotics [<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Antipsychotic polypharmacy [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Use of antidepressants [<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of first-generation antipsychotics [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Receiving psychotherapy [<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of long-acting injectables [<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of second-generation antipsychotics [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Inpatient treatment [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Extrapyramidal, autonomic, and/or hormonal adverse effects [<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of anticholinergics/anti-Parkinsonian drugs [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>,<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of anxiolytics/hypnotics [<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of mood stabilizers [<xref rid="B87-brainsci-14-00006" ref-type="bibr">87</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Greater number of hospital admissions [<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of treatment [<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being under involuntary treatment [<xref rid="B52-brainsci-14-00006" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Illness factors</td><td align="center" valign="middle" rowspan="1" colspan="1">First-episode psychosis patients (for those on second-generation antipsychotics) [<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of illness (for those on first-generation antipsychotics) [<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Greater severity of psychopathology [<xref rid="B19-brainsci-14-00006" ref-type="bibr">19</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B68-brainsci-14-00006" ref-type="bibr">68</xref>,<xref rid="B90-brainsci-14-00006" ref-type="bibr">90</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current psychotic episode [<xref rid="B89-brainsci-14-00006" ref-type="bibr">89</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="brainsci-14-00006-t002" orientation="portrait"><object-id pub-id-type="pii">brainsci-14-00006-t002_Table 2</object-id><label>Table 2</label><caption><p>Antipsychotic polypharmacy and clinical correlates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Increased Frequency of Antipsychotic Polypharmacy </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Decreased <break/> Frequency of Antipsychotic Polypharmacy </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Socio-demographic factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Being Caucasian [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Being married [<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being disabled [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Older age [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>,<xref rid="B105-brainsci-14-00006" ref-type="bibr">105</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Living in a rural area [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Being African-American or of a minority group [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Living alone [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Receiving early retirement pension [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Better mental quality of life [<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being male [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being female [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Treatment factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Prior or current clozapine use [<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Involuntary admission [<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On first-generation antipsychotics [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Use of risperidone as principal treatment [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On long-acting injectables [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Less satisfaction with treatment [<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On antidepressants [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased frequency of outpatient visits to psychiatry services (for users new to antipsychotic polypharmacy) [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On mood stabilizers, including lithium [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of treatment/time to treatment discontinuation [<xref rid="B41-brainsci-14-00006" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On anti-Parkinsonian drugs [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Greater number of inpatient visits [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On anticholinergic agents [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">On benzodiazepines [<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Use of quetiapine/paliperidone as principal treatment [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Poor adherence to antipsychotic treatment [<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Antipsychotic exposure or concomitant treatment with other psychoactive drugs [<xref rid="B27-brainsci-14-00006" ref-type="bibr">27</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being on more classes of psychotropics [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Higher antipsychotic doses [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">High-dose antipsychotic prescription [<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>,<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On maintenance therapy [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Hospitalization of &gt;30 days [<xref rid="B75-brainsci-14-00006" ref-type="bibr">75</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Higher number of emergency services visits [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being institutionalized [<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Inpatient treatment in the past year [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Higher self-paying cost of treatment [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Receiving electroconvulsive therapy [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Higher frequency of outpatient visits to psychiatry services [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of treatment [<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Medication non-adherence/poor treatment compliance [<xref rid="B48-brainsci-14-00006" ref-type="bibr">48</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Greater number of hospitalizations [<xref rid="B50-brainsci-14-00006" ref-type="bibr">50</xref>,<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On benzodiazepines/anxiolytics/hypnotic drugs [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B107-brainsci-14-00006" ref-type="bibr">107</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Illness factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of illness [<xref rid="B28-brainsci-14-00006" ref-type="bibr">28</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B105-brainsci-14-00006" ref-type="bibr">105</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Comorbid depression [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">More psychiatric comorbidities [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Comorbid anxiety [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">In a current episode of schizophrenia, or symptomatic [<xref rid="B38-brainsci-14-00006" ref-type="bibr">38</xref>,<xref rid="B40-brainsci-14-00006" ref-type="bibr">40</xref>,<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Delirium [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Mental retardation [<xref rid="B45-brainsci-14-00006" ref-type="bibr">45</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Higher level of functioning [<xref rid="B54-brainsci-14-00006" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Weight loss/malnutrition [<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Older age of onset [<xref rid="B63-brainsci-14-00006" ref-type="bibr">63</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Presence of substance use disorder/drug abuse [<xref rid="B51-brainsci-14-00006" ref-type="bibr">51</xref>,<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B60-brainsci-14-00006" ref-type="bibr">60</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Alcohol abuse [<xref rid="B58-brainsci-14-00006" ref-type="bibr">58</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">More medical comorbidities [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B100-brainsci-14-00006" ref-type="bibr">100</xref>,<xref rid="B104-brainsci-14-00006" ref-type="bibr">104</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Presence of substance use disorder [<xref rid="B99-brainsci-14-00006" ref-type="bibr">99</xref>,<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More medical/physical comorbidities [<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="brainsci-14-00006-t003" orientation="portrait"><object-id pub-id-type="pii">brainsci-14-00006-t003_Table 3</object-id><label>Table 3</label><caption><p>Mood stabilizer use and clinical correlates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Increased Frequency of Mood Stabilizer Use </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors Associated with Decreased <break/> Frequency of Mood Stabilizer Use </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Socio-demographic factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Being female [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Older age [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>,<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Age &#8805; 50 years [<xref rid="B96-brainsci-14-00006" ref-type="bibr">96</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being male [<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Being Caucasian [<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Country/study site [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Illness factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Hospitalization status [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of illness [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Longer duration of illness [<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Greater number of hospitalizations [<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B88-brainsci-14-00006" ref-type="bibr">88</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Hallucinations [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Behavioral or verbal disorganization [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Negative symptoms [<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Aggression/hostility [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>,<xref rid="B69-brainsci-14-00006" ref-type="bibr">69</xref>,<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Cardiovascular diagnoses [<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Affective symptoms [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Depressive symptoms [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Social-occupational dysfunction [<xref rid="B65-brainsci-14-00006" ref-type="bibr">65</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Comorbid psychiatric conditions [<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Previous suicidality [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Substance abuse [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Had one or more psychoses that required hospitalizations [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Treatment factors</td><td align="center" valign="middle" rowspan="1" colspan="1">Antipsychotic polypharmacy [<xref rid="B102-brainsci-14-00006" ref-type="bibr">102</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">On anti-Parkinson&#8217;s medication [<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On antidepressants [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">On benzodiazepines [<xref rid="B110-brainsci-14-00006" ref-type="bibr">110</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">History of antiepileptic use [<xref rid="B109-brainsci-14-00006" ref-type="bibr">109</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of antipsychotic and mood stabilizer use [<xref rid="B79-brainsci-14-00006" ref-type="bibr">79</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>